we can see | the end of cancer | from here

someday
is today

LEUKEMIA & LYMPHOMA SOCIETY®
fighting blood cancers

2013 annual report
someday | there’ll be a cure for cancers. But why can’t we end them now, the way we sent other diseases packing? We can. You can make it happen. This is the most momentous time of cancer research ever. The end of many cancers is almost within reach. To reach that end, it will take continued research. For over 60 years, The Leukemia & Lymphoma Society has helped pioneer innovations once thought impossible: multi-drug chemotherapy, stem-cell transplantation, and other treatments that have changed the landscape of blood cancers. Leukemia medicines like Gleevec®
are now used to treat patients with other cancers. Velcade®, approved for myeloma patients, is now being tested against lung, brain, breast, colon and prostate cancers. LLS saves lives by bringing better therapies to today’s cancer patients. If all of us concentrate our funds and volunteer our efforts through LLS, we will create a force for good that will bring down these diseases sooner. We can really do this. The power of millions starts with one heart deciding: Someday has got to be today. With one individual declaring: Cancer ends with me | is today
Last year was a period of significant investment in launching “Someday is Today” as an expression of our organization’s commitment to ending blood cancers. This is more than a tagline for LLS. It is a statement of our belief in the progress being made against blood cancers. And it is even more true now than it was just 12 months ago. As a result of the daring research LLS is sponsoring and the policies we are advocating, more lives are being saved, more patients are able to afford the miraculous treatments we help to advance, and we are closing in on several blood cancers.

It is thrilling to say we can see the end of any cancer from here. We can see it in the faces of the new generation of cancer survivors whose portraits grace this year’s report, and who represent thousands of other patients who are in remission or are living normal lives, some managing their condition with only a daily pill.

We can see it in the scientific advances we’ve made happen. Take T-cell immunotherapies, which have received considerable press this year because they can train a patient’s own immune system to seek out and kill cancer cells specifically. LLS has been funding teams pursuing this approach since 1992, and progress is continuing to happen. Because of the expertise of our research staff and medical and scientific advisory board, LLS has deep perspective and insight on which approaches might really work.

Other progress includes our success in working with the FDA and legislators at the federal and state level. We have a unique opportunity to help put the FDA in a better position to understand the science, the medicine and the patient need. This can ease potential bottlenecks in moving therapies through the regulatory evaluation process. We spent more than $50 million this year to help 44,000 patients afford their treatment, and we sounded our strong voice in statehouses and the halls of Congress to advocate for access to treatments for all blood cancer patients.

Advancing against a serious enemy like cancer requires mobilizing our most effective forces. Most charities still operate the way they have for 50 years: They wait for scientists to approach them with ideas. LLS takes a different tack. LLS pursues a research agenda with our medical and scientific advisory board. For a significant part of our research funding, we decide proactively where our dollars are likely to have the greatest impact. For those parts of our work, we go to the researchers instead of waiting for them to come to us. And we have been able to do this while also keeping the tried and true traditional research-funding approach as part of our portfolio.

Today LLS is in an extraordinary position to act as a catalyst for collaboration. We increasingly have been able to bring together the most important players in the ecosystem of innovation: Academic researchers, biotech and pharmaceutical companies, physicians, healthcare providers, third party payers, the FDA. Rather than work independently of one another, these parties are finding it advantageous to align their interests with ours. This is a watershed development.

Yet, with all this achievement, we continue to lose someone to a blood cancer every 10 minutes.

One such person was Kethan, diagnosed at age four with acute lymphoblastic leukemia. LLS is an organization that will move heaven and earth to help a single person; but despite LLS’s efforts to give Kethan access to an experimental treatment after numerous remissions over seven years, he succumbed to pneumonia in July. The death of a beautiful 11-year-old boy reminds us how much more we have to do, and why your support has never been more crucial.

John E. Walter. President & CEO. Timothy S. Durst. Chair.
as a unique catalyst for collaboration LLS advances innovation by bringing all the right players together.

LLS is well positioned to align the key players in the ecosystem of cancer innovation. This has led to new and groundbreaking partnerships:

- **LLS’s Therapy Acceleration Program®** added many new partners from biopharmaceutical industry and academic institutions. One of the most important was the Knight Cancer Institute at Oregon Health & Science University (OHSU). The Beat AML initiative, led by Brian Druker, MD, includes major technology companies like Intel, which provides big data computing technology, and Illumina, which provides advanced genetic sequencing. The goal is to identify the many mutations that drive acute myeloid leukemia and identify drugs that can target these mutations.

- In July 2013, LLS announced a partnership with **Johns Hopkins University School of Medicine** to advance a novel immunotherapy for patients with poor prognosis myeloma. Under the leadership of Ivan Borrello, MD, researchers are testing a method using immune system T-cells that are specifically trained to recognize and kill myeloma cells. The approach shows promise for patients with other blood cancers as well.

- In June 2013, **Dana-Farber Cancer Institute** joined LLS to establish clinical testing of innovative blood cancer therapies in community oncology settings across the country.

THE BLOOD CANCER RESEARCH PARTNERSHIP WILL BRING CLINICAL TRIALS TO PATIENTS WHERE THEY LIVE

This unprecedented Blood Cancer Research Partnership will bring clinical trials to patients where they live and address one of the primary bottlenecks to new cancer therapies: the need for more patients to take part in trials.

- LLS committed funding to **Valor Biotherapeutics, LLC**, a joint venture between ImmunGene and Caliber companies, to develop a novel protein therapeutic that may improve outcomes for many patients with indolent lymphomas who do not respond to standard therapy with Rituxan®. Valor’s biotherapeutic is produced by fusing lymphoma-seeking antibodies to tumor-cell-killing proteins in a single, genetically engineered molecule.

- **The APL Project**: LLS initiated a project with Anand Jillella, MD, Chief of Hematology, Oncology and Bone Marrow Transplant at Emory University, to reduce the mortality rate for patients diagnosed with acute promyelocytic leukemia (APL) by providing community oncologists/hematologists with a simple, optimized treatment protocol for the care of newly diagnosed patients with APL, a rare molecular subtype of acute myeloid leukemia.

- LLS partnered with **Affimed Therapeutics AG** to co-fund a phase 2 trial of a novel multi-targeted antibody in Hodgkin lymphoma (HL) patients for whom currently available treatments have failed. This therapeutic is directed against two different molecules, CD30 and CD16A, to bring cancer-killing immune cells directly to the HL cells. It is a first-in-class immunotherapy designed to treat HL patients and patients with other CD30-positive malignancies.
**NEW GRANTS PROGRAMS IN 2013**

**LLS unveiled new grants programs this year:**

- **New Idea.** This is a new grant program designed to identify highly novel research strategies with potential to fundamentally increase our understanding of specific blood cancers and significantly change the way blood cancer patients are diagnosed and treated. This program supports academic researchers with approaches that are likely to help improve patient outcomes. The researchers will receive a one-year $100,000 grant.

- **Screen to Lead.** LLS also recently solicited applications from researchers who are identifying (screening) potential drugs that inhibit recently discovered cancer-driving molecules (targets) and/or optimizing the chemical properties of novel inhibitors. This Screen to Lead initiative acknowledges a significant need to help investigators discover and improve drug-like compounds that can be further tested in the lab and in the clinic.

- **Quest for Cures.** In February 2013, LLS asked the academic researcher community to propose research focusing on three priority areas: Monitoring tumor cell heterogeneity and its contribution to response or resistance to therapy; molecular mechanisms to identify and direct subsets of patients with B-cell malignancies to the right therapy; and the role of the tumor microenvironment in initiation and maintenance of blood cancers. Quest for Cures is enabled by funding from Celgene through our new Targets Leads & Candidates Program®. This program identifies and funds priority research areas, with support from biotechnology and pharmaceutical company partners.

LLS continues to support the development of breakthrough cancer therapies in academic settings, committing substantial funding to researchers around the world.

**LLS RESEARCH MILESTONES**

- **Celator.** Our Therapy Acceleration Program passed an important milestone in January 2013 when Celator announced enrollment of the first patient in the phase 3 clinical trial of a novel drug formulation, CPX-351, for older patients with especially high-risk cases of acute myeloid leukemia (AML).

CPX-351 employs a novel technology to ensure that the most effective ratio of two standard drugs gets directly to the leukemia cells, and that leukemia cells are preferentially killed. This is an example of a promising therapy that might otherwise not be developed because it benefits a small patient population. We hope the phase 3 trial will ultimately support approval of a much-needed treatment option for AML patients, for whom there have been few advances over the past three decades.

- **Curis, Inc.**, a drug development company seeking to develop next-generation targeted anti-cancer drugs, announced that the first patient has been treated in a phase 1 clinical study of a new drug, CUDC-907, for patients with relapsed or refractory lymphoma or multiple myeloma.

CUDC-907 is a first-in-class oral drug designed as a dual inhibitor of two enzyme classes that are both abnormally active in many cancers, known as phosphatidylinositol-3-kinase (PI3K) and histone deacetylase (HDAC).

- **Constellation Pharmaceuticals, Inc.**, is focused on the emerging area of “epigenetics,” i.e. non-mutation changes to genes and gene-binding proteins that, like gene mutations, can promote cancers. The company announced that it has initiated a phase 1 clinical trial of CPI-0610, a novel inhibitor of the “BET” family of gene-binding proteins, in patients with previously treated and progressive lymphomas.
This first-in-human trial is currently open at The Sarah Cannon Research Institute in Nashville, Tennessee and at the John Theurer Cancer Center in Hackensack, New Jersey. Additional U.S. study sites will join the trial over the next several months. Studies of CPI-0610 are also planned in patients with multiple myeloma and in patients with acute leukemias or myelodysplastic syndromes.

VENTURE PHILANTHROPY: LLS LEADS THE WAY IN CANCER INNOVATION

LLS provides the seed money to encourage innovative research in areas of unmet medical need. This high-risk, high-reward strategy is helping save lives through partnerships with universities and biotechnology companies, giving critical support to research and advancing therapies that might otherwise go undeveloped.

In fiscal year 2013, LLS venture philanthropy leadership was underscored when three LLS Therapy Acceleration Program (TAP) partners saw major business transactions that made the headlines.

In 2011, LLS partnered with Epizyme to drive the early development of a DOT1L-targeted therapy for patients with mixed lineage leukemia. In fiscal year 2013, the importance of this project was recognized by a $90 million licensing partnership with Celgene Corporation and a subsequent Epizyme initial public offering (IPO) in May.

In 2010, LLS entered a partnership with Onconova Therapeutics, Inc. to support a phase 3 clinical trial testing rigosertib, a novel multi-kinase inhibitory agent in the treatment of high-risk myelodysplastic syndromes. In fiscal year 2013, the importance of the project was recognized by a $50 million licensing partnership with Baxter International Inc. and a subsequent IPO by Onconova. This IPO, in July 2013, raised almost $78 million, which will support continued development of rigosertib.

In 2011, LLS partnered with Acetylon Pharmaceuticals, Inc. to accelerate the development of a novel treatment for multiple myeloma. The innovative nature of this project was recognized in fiscal year 2013 when Celgene Corporation signed a $100 million agreement to further develop Acetylon’s group of HDAC6-selective histone deacetylase (HDAC) inhibitors.

In each case above, large pharmaceutical companies and the public markets recognized the promise of new therapies being supported by LLS by making significant additional investments. These investments enable our biotechnology partners to overcome risk thresholds and move promising new treatments forward.
Not only is LLS helping to move therapies faster through the research process, but our LLS mission team continues to ensure that all blood cancer patients have access to the best treatments.

We implemented a regionalization plan to form strong teams that are better positioned to drive our cures and access agenda.

New regional mission director roles were created to strengthen our delivery of mission in the field to help ensure the best available care for blood cancer patients. We also created the role of regional state government affairs directors to deepen our relationships with key policymakers at the state level and put LLS in a leadership role to advocate for access.

**Affordable Care Act.** Open enrollment in the new marketplaces (also known as exchanges) began October 1st. LLS has been working to help patients and their families understand how enrolling in these insurance plans in the exchanges may impact them. There are many factors to consider other than the policy premium, including whether certain therapies will be covered and what a patient will incur in out-of-pocket expenses.

---

**LLS HAS CREATED A SPECIAL SECTION ON OUR WEBSITE LLS.ORG TO HELP PATIENTS KNOW THE RIGHT QUESTIONS TO ASK WHEN REVIEWING HEALTH INSURANCE PLAN OPTIONS**

- **Specialty tiers bill: 72 co-sponsors and counting.** You’ve spoken up about the importance of stopping unfair cost-sharing practices from keeping crucial medications out of reach for many cancer patients. And 72 members of Congress have listened.

  Thanks in part to your letters, calls, personal stories and in-person meetings both on Mission Day and every day, these representatives have signed on as co-sponsors of the Patients’ Access to Treatments Act (HR 460).

- **Mission Day** was a resounding success for us in Washington, DC. We held almost 250 meetings on Capitol Hill, nearly a third of which were with members of Congress and the remainder with Congressional staff. We are now hearing from staff on both sides of the aisle about their interest in supporting HR 460.

  We were honored to have Emmy Award-winning New York Times Well columnist **Suleika Jaouad**, an AML and MDS survivor, join us for meetings on Capitol Hill. See her post mentioning Mission Day in her column, *Life, Interrupted*. **
As a donor-supported organization, it’s one thing to talk about finding cures and ensuring access to the best available treatments for all blood cancer patients. It’s another to convince people we are succeeding in our mission—and to create a sense of urgency. That is why we have stepped up our communications efforts over the last year, with remarkable results.

**SOMEDAY IS TODAY**

- **LLS launched a powerful new branding platform** in February with a public service announcement airing on national cable and broadcast outlets. The goal is to ensure patients know that LLS is a trusted source of education and support, and to highlight the many ways that LLS is changing the landscape of cancer.


LLS upgraded the web site to showcase the new branding platform, with a special landing page for Someday is Today; a “Someday People” gallery of survivor stories; and a Someday is Today video gallery.

“We felt it was time to rally support by shining the spotlight on our work to find cures and ensure access to treatments for all blood cancer survivors,” says John Walter, LLS CEO. “People talk about curing cancer at some point in the future, but for LLS, someday is today. Contributions made to this organization through partners, volunteers and generous donors are driving cures right now.”

Our ad placement during the Robin Roberts interview on ABC’s *20/20* generated a spike in traffic to our website and social media channels. On a typical Friday, LLS sees about 6,500 hits to the site, but on Friday, February 22, we had 2,068 more hits than average, for a total of 8,515 visits. This was a significant 32% jump.

The combination and full effect of the national and regional advertising, along with a publicity blitz and a strong social media presence, will continue to create excitement and engagement with LLS in the months to come.

**SIT 2.0 CAMPAIGN TO LAUNCH**

We are preparing to launch Someday is Today 2.0 in fiscal year 2014, which makes the Someday is Today theme even more personal by inviting people to realize that *Cancer Ends with Me* and to declare their support.
Blood Cancer Awareness Month. In September 2013, LLS took full advantage of this month-long opportunity to showcase our role in advancing treatments to the widest possible audience. We shared results of a survey that reveals an alarming lack of knowledge among adults of all ages about blood cancers. Less than half polled believe that blood cancers are one of three leading causes of cancer death in the U.S., despite blood cancers being the third leading cause of cancer death. Four in five adults (82%) were surprised to learn that more than one million U.S. adults are currently living with a blood cancer.

Hispanic program. During fiscal year 2013 we developed an integrated Hispanic Market action plan that will generate awareness of LLS and its free Spanish language services via multiple channels; engage potential patients, volunteers, donors, and advocates; and form relationships with key influencers and community leaders.

We are building an independent Spanish language LLS web site that employs consistent LLS branding and clear Spanish language navigation; and rolling out Someday Is Today (Algun Dia es Hoy) in 10 major US markets.

Nike Women’s Marathon. A new Nike Women’s Half Marathon in Washington, DC, was added in fiscal year 2013. To date, through the fundraising efforts of our participants, the Nike race series has generated more than $132 million to help LLS advance life-saving therapies and ensure access for patients.

Team In Training 25. In January 2013, we kicked off our celebration of the 25th anniversary of Team In Training (TNT). More than 600,000 TNT fundraising participants have raised $1.4 billion to date.

Rye, New York resident Bruce Cleland started TNT in 1988 by forming a team to run the New York City Marathon while raising funds for LLS in honor of his daughter, Georgia, who was diagnosed at age two with ALL: “I was trying to get past feelings of such helplessness and fear,” said Cleland. “At the time she was diagnosed, the five-year survival rate for young children like Georgia with ALL was only around 50 percent. A deep desire to help her and others like her was my fuel, and day after day it literally got me up on my feet, out onto the road and eventually over the finish line.”

This team of 38 runners raised $320,000 for LLS’s Westchester/Hudson Valley Chapter in New York. Thanks to the pioneering efforts of Cleland and the Westchester/Hudson Valley Chapter, TNT was born.

Georgia’s story is the embodiment of LLS’s mission. Now 29 and cancer-free, Georgia completed three TNT half-marathons in 2012 and her fourth, the Nike Women’s Marathon, in 2013.
yolanda | survivor | lymphoma
This year, our New York City chapter launched a new fundraising program under the TNT umbrella, called Moms In Training. The program involved 196 moms who have raised $325,000 this year for LLS. Plans are to expand the successful new campaign to 20 chapters next year.

Our 2013 Man & Woman of the Year campaign exceeded last year’s record, raising $22.8 million. In its 23rd year, more than 850 dynamic community leaders participated as candidates and collectively surpassed last year’s fundraising record by $3.6 million. Sixteen-year-old San Antonio leukemia survivor Daniel Edelen and Illinois resident Barbara Bernick earned the titles of national Man of the Year and Woman of the Year. Edelen is the youngest national title winner in the campaign’s history, raising an astounding $466,000—the most ever raised by any Man & Woman of the Year candidate to date. Bernick raised $232,050 in memory of her mother, who died from leukemia 20 years ago.

School & Youth. More than 29,000 schools participated in the School & Youth programs in 2013, raising a total of $27.7 million nationally this year. A new School & Youth fundraising record was set by Walt Whitman High School from the Washington, DC, metro area, whose students raised a total of $91,761.16—the most ever raised by a school in the program’s history.

Light The Night Walk fiscal year 2013 concluded another successful season, with participants in the U.S. and Canada raising nearly $56 million.

For the 12th consecutive year, Burlington has served as the number-one national corporate partner and honored friend of the Light The Night Walk campaign, raising more than $3.4 million. In total, Burlington employees and customers have raised more than $16 million to benefit LLS.

Leukemia Cup Regatta. More than 10,000 sailors and their friends participated in Leukemia Cup Regattas throughout North America in fiscal year 2013, raising more than $4 million. The top fundraising Leukemia Cup took place at the San Francisco Yacht Club and raised more than $800,000, with Ted Turner serving as the VIP speaker. Since its inception, the Leukemia Cup Regatta has raised more than $46 million, with renowned sailor Gary Jobson serving as national chair. Jobson, a lymphoma survivor, has chaired the Leukemia Cup series since 1993. More than 100 top fundraisers from the Leukemia Cup Regattas participated in the Fantasy Sail with Jobson in New Orleans.

TARGETED GIVING AND BEQUESTS

The Edward P. Evans Foundation dedicated $5 million over five years to fund a new research initiative focused on myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). This is one of the largest major gifts in our history.

The Paul E. Singer Foundation is providing $1.875 million to support a TAP project under way at Weill Cornell Medical Center.

This year, LLS received more than $4 million in bequests of all sizes, and we welcomed many new members to our Legacy Circle.

MY LLS FREE FUNDRAISING MOBILE APP

My LLS app. LLS is adapting mobile tools and applications to enhance our fundraising in real time. My LLS is a free mobile app that makes fundraising more fun and efficient for Team In Training and Light The Night Walk participants, volunteers and teams.

My LLS lets you accept credit card and check donations and deposit the funds directly to the LLS Team In Training or Light The Night bank account on your behalf via Android and iPhone, anytime, anywhere.
research grants

THE MARSHALL A. LICHTMAN SPECIALIZED CENTER OF RESEARCH

The Specialized Center of Research Program funds multi-disciplinary research by teams of leading-edge academic investigators that hasten the discovery and development of better treatments for leukemia, lymphoma and myeloma patients. A center is composed of at least three independent research programs that are integrated and supported by scientific core laboratories.

Jerry Adams, PhD
Walter & Eliza Hall Institute of Medical Research
Frederick Alt, PhD
Immune Disease Institute
Jon Aster, MD
Brigham & Women’s Hospital
John Byrd, MD 1
The Ohio State University
William Carroll, MD* New York University School of Medicine
Riccardo Dalla-Favera, MD 2 Columbia University Medical Center
Brian Druker, MD 3 Oregon Health & Science University
Irene Ghobrial, MD* Dana-Farber Cancer Institute
Anthony Green, MD, PhD University of Cambridge
Helen Heslop, MD* Baylor College of Medicine
Carl June, MD 4 University of Pennsylvania

1 Dr. John Byrd is funded in part by Rita Cavanagh & Gerald Kafka, The Jim Jacobs Charitable Foundation, Elaine Smith, Phyllis & Douglas A. Smith and Judy & Michael Thomas.

2 Dr. Riccardo Dalla-Favera is funded in part by The Paul E. Singer Family Foundation, the Joseph S. and Diane H. Steinberg Charitable Trust and the J.T. Tai & Co. Foundation, Inc.

3 Dr. Brian Druker is funded in part by The F.M. Kirby Foundation, Inc.

4 Dr. Carl June is funded in part by the Amanda Wins Fund and The Orokawa Foundation.

5 Dr. Jonathan Licht is funded in part by The Pamela B. Katten Memorial Leukemia Research Foundation.

6 Dr. Scott Lowe is funded in part by the Atchush Foundation - Reichman Memorial.

CAREER DEVELOPMENT PROGRAM (SCHOLARS AND CLINICAL SCHOLARS)

The Career Development Program provides stipends to investigators of exceptional promise in the early stages of their careers, helping them devote their careers to research in leukemia, lymphoma or myeloma.

Gregory Abel, MD
Dana-Farber Cancer Institute
K Mark Ansel, PhD
University of California, San Francisco
Scott Armstrong, MD, PhD
Children’s Hospital Boston
Craig Bassing, PhD
The Children’s Hospital of Philadelphia
Michael Boddy, PhD
The Scripps Research Institute
Jennifer Brown, MD, PhD Dana-Farber Cancer Institute
Patrick Brown, MD 5 Johns Hopkins University School of Medicine
Claudio Brunstein, MD, PhD University of Minnesota - Twin Cities
Jan Burger, MD, PhD* University of Texas M.D. Anderson Cancer Center
George Cailin, MD University of Texas M.D. Anderson Cancer Center
Iain Cheeseman, PhD Whitehead Institute for Biomedical Research
Jing Chen, PhD Emory University
Yuh Min Chook, PhD University of Texas Southwestern Medical Center
Christopher Cogle, MD University of Florida
Yali Dou, PhD University of Michigan
Mary Eapen, MD 3 Medical College of Wisconsin
Benjamin Ebert, MD, PhD Brigham and Women’s Hospital, Inc.
David Ferguson, MD, PhD University of Michigan
Elsa Flores, PhD University of Texas M.D. Anderson Cancer Center
Maxim Frolov, PhD University of Illinois - Chicago
Andrei Goga, MD, PhD University of Michigan
Andrea Goluch, PhD University of California, San Diego
Ayaj Gopal, MD 12 University of Washington
Jolanta Grembecka, PhD* University of Michigan
Jonathan Higgins, PhD Brigham and Women’s Hospital, Inc.

Marina Konopleva, MD, PhD University of Texas M.D. Anderson Cancer Center
John Koreth, MD, PhD* Dana-Farber Cancer Institute
Rhithe Kovvali, PhD University of Cincinnati
Ross Levine, MD Memorial Sloan-Kettering Cancer Center
Mark Leis, MD, PhD 11 Johns Hopkins University School of Medicine
Ivan Maillard, MD, PhD* University of Michigan
Sam Malek, MD University of Michigan
William Matsui, MD 12 Johns Hopkins University School of Medicine
Hanna Mikkola, MD, PhD 13 University of California, Los Angeles
Golam Mohi, PhD* SUNY Upstate Medical Center
James Mulloy, PhD Children’s Hospital Medical Center-Cincinnati
Markus Muschen, MD, PhD University of Michigan
Kyung-Oa Oh, PhD University of California, San Francisco
Ryoma Ohi, PhD* Vanderbilt University Medical Center
Emmanuelle Passegé, PhD University of California, San Francisco
Cathie Pfleger, PhD Mount Sinai School of Medicine
Joel Pomerantz, PhD Johns Hopkins University School of Medicine

Noopur Raje, MD 14 Massachusetts General Hospital
Jeffrey Rathmell, PhD Duke University Medical Center
Pavan Reddy, MD University of Michigan
Boris Reizis, PhD Columbia University Medical Center
James Rubenstein, MD, PhD University of California, San Francisco
Loredana Ruggeri, MD, PhD University of Perugia
Davide Ruggero, PhD University of California, San Francisco
Julien Sage, PhD Stanford University
Tala Salz, PhD* Memorial Sloan-Kettering Cancer Center
Karsten Sauer, PhD The Scripps Research Institute Joseph Scandura, MD, PhD* Well Medical College of Cornell University Neil Shah, MD, PhD University of California, San Francisco
Tait Shanafelt, MD Mayo Clinic and Foundation
Jane Skok, PhD New York University School of Medicine
Merav Socolovsky, MD, PhD University of Massachusetts Medical School
Kimberly Stegmaier, MD* Dana-Farber Cancer Institute
Enrico Tiacchi, MD* University of Perugia

15 Dr. Beverly Mitchell is funded in part by The Orokawa Foundation.

8 Dr. Patrick Brown is fully funded by The Orokawa Foundation.

7 Dr. Mary Eapen is funded in part by The Greater Milwaukee Foundation, Inc.

9 Dr. Beverly Mitchell is funded in part by The John J. Hanker Foundation.
The Career Development Program provides stipends to investigators of exceptional promise in the early stages of their careers, helping them devote their careers to research in leukemia, lymphoma or myeloma.

Alison Adams, PhD*  
Yale University  
Cassandra Adams, PhD  
University of California, San Francisco  
Colin Atkin, PhD  
Johns Hopkins University School of Medicine  
Koshi Akahane, MD, PhD*  
Dana-Farber Cancer Institute  
Lukas Baitsch, PhD  
Dana-Farber Cancer Institute  
Ami Bhatt, MD, PhD*  
Dana-Farber Cancer Institute  
Kivanc Birsoy, PhD*  
Whitehead Institute for Biomedical Research  
Jessica Blackburn, PhD*  
Massachusetts General Hospital  
Vincenzo Calvanese, PhD*  
University of California, Los Angeles  
Tiffany Chang, MD*  
University of California, San Francisco  
Daniel Herranz, PhD  
Cancer Center Memorial Sloan-Kettering  
Yoon-Chi Han, PhD  
Memorial Sloan-Kettering Cancer Center  
Mo Chen, PhD  
The Rockefeller University

Hauke Cornils, PhD  
Dana-Farber Cancer Institute  
Matthew Davids, MD  
Dana-Farber Cancer Institute  
David Dilillo, PhD  
The Rockefeller University  
Jonathan Driver, PhD*  
University of Washington  
Chihang Duy, PhD  
Well Medical College of Cornell University  
Anna Eiring, PhD  
University of Utah  
Chen Fang, PhD*  
Fred Hutchinson Cancer Research Center  
Xiaofei Gao, PhD*  
Whitehead Institute for Biomedical Research  
Charles Gawad, MD*  
Stanford University  
Luke Gilbert, PhD*  
University of California, San Francisco  
Saar Gill, MD*  
University of Pennsylvania  
Evisi Gjin, PhD  
Dana-Farber Cancer Institute  
Michael Green, PhD  
Stanford University  
Sarah Hainer, PhD*  
University of Massachusetts Medical School  
Yoon-Chi Han, PhD  
Memorial Sloan-Kettering Cancer Center  
Daniel Herranz, PhD  
Columbia University Medical Center  
Erin Hertlein, PhD  
The Ohio State University

Andrew Holland, PhD  
Ludwig Institute for Cancer Research  
Kuo-Chiang Hsia, PhD  
The Rockefeller University  
Enfu Hui, PhD  
University of California, San Francisco  
Alexandre Iannello, PhD*  
University of California, Berkeley  
Caron Jacobson, MD*  
Dana-Farber Cancer Institute  
Ana Janic, PhD  
Walter and Eliza Hall Institute of Medical Research  
Jared Johnson, PhD  
Beth Israel Deaconess Medical Center  
Brian Jonas, MD, PhD  
Stanford University  
Christopher Kanakry, MD*  
Johns Hopkins University  
Hyungjin Kim, PhD  
Dana-Farber Cancer Institute  
Mi-Yeon Kim, PhD  
Columbia University Medical Center  
Julianne Kitesvki-LeBlanc, PhD  
University of Toronto  
Maria Kieppe, PhD*  
Memorial Sloan-Kettering Cancer Center  
Myung Ko, PhD  
La Jolla Institute for Allergy & Immunology  
Andrew Koh, PhD  
Stanford University  
Holbrook Kohr, MD  
Stanford University  
Andrew Lane, MD, PhD  
Dana-Farber Cancer Institute  
Yan Li, PhD  
University of Pennsylvania  
Kalfeng Lin, PhD  
University of North Carolina at Chapel Hill  
Kevin Lin, PhD  
British Columbia Cancer Agency  
Xiangyu Liu, PhD*  
Columbia University Medical Center  
Camille Lobry, PhD  
New York University School of Medicine  
Alexis Lomakin, PhD  
Harvard Medical School  
Sidinuc, PhD*  
Children’s Hospital Boston  
Zhuojuan Luo, PhD*  
Stowers Institute for Medical Research  
Julia Maxson, PhD*  
Oregon Health & Science University  
Jeffrey McKnight, PhD*  
Fred Hutchinson Cancer Research Center  
Megan McNerney, MD, PhD  
The University of Chicago  
Sarah Mitchell, PhD  
University of Colorado at Boulder  
Jagan Muppidi, MD, PhD  
University of California, San Francisco  
John Reagan, MD*  
Rhode Island Hospital  
Kathryn Roberts, PhD*  
St. Jude Children’s Research Hospital  
Voytek Okreglok, PhD  
California Institute of Technology  
Claudio Scuoppo, PhD*  
Columbia University Medical Center  
Lev Silberstein, MD, PhD  
Massachusetts General Hospital  
Tonis Org, PhD  
University of California, Los Angeles  
Elisa Orlicchio, PhD*  
Memorial Sloan-Kettering Cancer Center  
Johnnie Orozco, MD, PhD  
Fred Hutchinson Cancer Research Center  
Ana Ortega Molina, PhD*  
Sloan-Kettering Institute for Cancer Research  
Christopher Ott, PhD  
Dana-Farber Cancer Institute  
Jae Park, MD  
Memorial Sloan-Kettering Cancer Center  
Daniel Pollyea, MD*  
University of Colorado  
Heather Pua, MD, PhD*  
University of California, San Francisco  
Alexandre Puissant, PhD  
Dana-Farber Cancer Institute  
Sarwish Rafiq, PhD*  
Memorial Sloan-Kettering Cancer Center  
Kaushik Ragunathan, PhD*  
Harvard Medical School  
Parvathi Ranganathan, PhD*  
The Ohio State University  
Jeffrey Skaar, PhD  
New York University School of Medicine  
Richelle Sopko, PhD  
Harvard Medical School  
Jamie Spangler, PhD  
Stanford University  
Till Strowig, PhD  
Yale University  
Mayumi Sugita, MD  
University of Pennsylvania  
Kendra Sweet, MD*  
H. Lee Moffitt Cancer Center & Research Institute  
Yvonne Tay, PhD  
Beth Israel Deaconess Medical Center  
Benjamin Thompson, PhD  
Northwestern University  
Sarah Thompson, MD, PhD  
University of Manchester  
Shih-Chieh Ti, PhD*  
The Rockefeller University  
Joanna Tober, PhD*  
University of Pennsylvania  
Gianluca Varetti, PhD*  
Dana-Farber Cancer Institute  
Roumen Voutev, PhD  
Columbia University Medical Center  
Youzhong Wan, PhD  
Dana-Farber Cancer Institute  
Lin Wang, PhD  
University of California, Berkeley  
Matthew Warr, PhD  
University of California, San Francisco  
Rei Watanabe, MD, PhD  
Brigham and Women’s Hospital, Inc.  
Nathan Westcott, PhD*  
The Rockefeller University

10 Dr. Ajay Gopal is fully funded by Genentech, Inc.  
11 Dr. Mark Levis is the Rally Foundation for Childhood Cancer Research Scholar.  
12 Dr. William Matsui is the Millennium: The Takeda Oncology Company Scholar.  
13 Dr. Hanna Mikkola is funded in part by Parents Against Leukemia.  
14 Dr. Noopur Raje is the Millennium: The Takeda Oncology Company Scholar.  
15 Dr. Chihang Duy is funded in part by the Jake Wetchler Fellowship for Pediatric Innovation.  
16 Dr. Chen Fang is fully funded by Kent A. Torpik.  
17 Dr. Eisa Orlicchio is fully funded by the Gertrude B. Eliot Endowment Fund.  
18 Dr. Daniel Pollyea is funded in part by Jack A. Torpik.  
19 Newly awarded or renewed grants in fiscal year 2013
The Translational Research Program supports outstanding investigations deemed by our expert advisors most likely to translate basic biomedical discoveries into new, safe and effective treatments, ultimately prolonging and enhancing patients’ lives.

Shabbir Aliabadi, MD
University Health Network
Stephen Ansell, MD, PhD
Mayo Clinic and Foundation
Saro Armenian, DO, MPH
Beckman Research Institute of the City of Hope

Dr. Stephen Ansel is funded in part by Laurie Adami and Ben Robertson.

21 Dr. Saro Armenian is funded in part by the California Community Foundation and The Rally Foundation for Childhood Cancer Research.

22 Dr. John Byrd is funded in part by Rita Cavanagh & Gerald Kafka.

23 Dr. Selina Chen-Kiang is funded in part by the LLS Maryland Chapter Researcher and is funded in part by the Cora and John H. Davis Foundation and Andrew F. Gulli.

24 Dr. Craig Jordan is funded in part by The Paul E. Singer Family Foundation.

25 Dr. Steven Mittelman is funded in part by The California Community Foundation.

26 Dr. Talal Agha is funded in part by Andrew F. Gulli.

27 Dr. Jeffrey Molldrem is funded in part by The Paul E. Singer Family Foundation.

28 Dr. Jeffrey Molldrem is the Imagine a Cure for Leukemia’s Translational Researcher.

29 Dr. Markus Muschen is funded in part by an anonymous donor.
Acute Lymphoblastic Leukemia

The Acute Lymphoblastic Leukemia Research Portfolio is funded in part by Megan’s Wings, Inc. and Deborah Tobias – Translational Research Program.

Acute Myeloid Leukemia and Myelodysplastic Syndromes


Chronic Lymphocytic Leukemia

The Chronic Lymphocytic Leukemia Research Portfolio is funded in part by Madeline & Stephen Anbinder, Rita Cavanagh & Gerald Kafka, Cora and John H. Davis Foundation, the George L. Shields Foundation, Inc., the Lumina Foundation, Marie McDermont and an anonymous donor.

Chronic Myeloid Leukemia

The Chronic Myeloid Leukemia Research Portfolio is funded in part by Leslie & Larry Nance.

Hodgkin Lymphoma

The Hodgkin Lymphoma Research Portfolio is funded in part by the Baltimore Tour de Court in memory of Rachel Minkove, Janet & Alex Boggs and Joyce Xavier Lennon.

Mantle Cell Lymphoma

The Mantle Cell Lymphoma Research Portfolio is funded in part by Josh Billings - Freeze Your Lymphs Off.

Myeloma and Waldenstrom Macroglobulinemia

The Myeloma and Waldenstrom Macroglobulinemia Research Portfolio is funded in part by the Names Family Foundation and David & Justine Springer Fund.

Aggressive Non-Hodgkin Lymphoma

The Aggressive Non-Hodgkin Lymphoma Research Portfolio is funded in part by Shirley & William Comely, Kathy and Joel James and the Slice of Lime Foundation.

Indolent Non-Hodgkin Lymphoma

The Indolent Non-Hodgkin Lymphoma Research Portfolio is funded in part by Nonnie & John Barby, Susan & Jay Clark, Cristine & Timothy Lindenfelter, Lois & Jerry Rosenberg and an anonymous donor.

Pediatric and Young Adult Blood Cancer

The Pediatric and Young Adult Blood Cancer Research Portfolio is funded in part by the Averin M. Cornell Foundation, Sandra & Noah Anderson, the Franklin American Mortgage Company, Sara and Tam Luhby, and the Thomas and Agnes Carvel Foundation.

Quality of Life

The Quality of Life Research Portfolio is funded in part by The Cherry Picker Foundation, The Escher Foundation, the Hamill Family Trust, the Hildurdega D. Becher Foundation, Inc., ICAP Services North America, LLC, and the Kass Family Foundation.

Stem Cell Transplantation Research Portfolio

The Stem Cell Transplantation Research Portfolio is funded in part by Sam & John Dinos.

Therapy Acceleration Program


Therapy Acceleration Program


Therapy Acceleration Program


Therapy Acceleration Program


Therapy Acceleration Program

The below listing is made up of individuals, foundations and corporations that generously supported LLS’s mission during this fiscal year.

**$1,000,000 AND ABOVE**

Laurie Adami and Ben Robertson*
Barclays
The Beer Store
Burlington
Celgene Corporation
Edward P. Evans Foundation
Genentech, Inc.
Wells Fargo
PVH
Rush Limbaugh
The Harry T. Mangurian, Jr. Foundation, Inc.*
John Kelenyi
Millennium: The Takeda Oncology Company
Novartis Pharmaceuticals Corporation
The Paul E. Singer Family Corporation
Novartis Oncology Company
John Kellenyi
The Pamela B. Katten Memorial Foundation
The Orokawa Foundation
Mari Anne Miller Trust
Microsoft
Mari Anne Miller Trust
The Orskaw Foundation
The Pamela B. Katten Memorial Leukemia Research Foundation Partners For A Cure
Pfizer, Inc.
PricewaterhouseCoopers LLP
Quintiles
Rally Foundation for Childhood Cancer Research
Runner’s World
Salesforce.com
SanDisk Corporation
Sanofi-Aventis U.S. LLC
Sanofi-Aventis U.S. LLC PS Security Service Federal Credit Union
Silicon Valley Bank
Silicon Valley Community Foundation
SMART Modular Technologies
Spectrum Pharmaceuticals, Inc.
St. Joseph-Ogden High School Stater Bros. Charities
Terumo BCT

**$100,000 – $499,999**

Amanda Wina Fund
Angen
Astellas USA Foundation
Austacco, Ltd.
Baker Botts, LLP
Bank of America Merrill Lynch
Biogen Idec
BMC
Bristol-Myers Squibb Company
CA Technologies
California Community Foundation*
Cancer Treatment Centers of America
CareFirst BlueCross BlueShield Carter’s, Inc.
CenturyLink
Anthony Cioce, Jr.
Citrix Systems, Inc.
The Coleman Foundation*
Cricket Communications, Inc.
Deloitte LLP
DialAmerica
Elbit Systems of America, LLC
Ernst & Young LLP
F.M. Kirby Foundation, Inc.*
FIS
Fleming’s Prime Steakhouse & Wine Bar
Foundation Beyond Belief
G-Form, Inc.
GEICO
Muriel Gertler Trust
GlaxoSmithKline
Global Franchise Group
Google
Imagine a Cure for Leukemia
International Waldenstrom’s Macroglobulinemia Foundation*
The Joseph C. Santillippo Memorial Fund at Saratoga Monte Sereno Community Foundation
Joseph S. and Diane H. Steinberg Charitable Trust*
Emily & Neil Kisher
Lang/Stiltz Family Fund
Cristine & Timothy Lindenfelser KPMG LLP
The Marge & Charles J. Schott Foundation*
Major League Baseball
Clyde Smith McGregor & LeAnn Pedersen Pope - in memory of Joan Kowing McGregor
Mercedes Benz
Metzger Law Group
Microsoft
Mari Anne Miller Trust
The Orskaw Foundation
The Pamela B. Katten Memorial Leukemia Research Foundation Partners For A Cure
Pfizer, Inc.
PricewaterhouseCoopers LLP
Quintiles
Rally Foundation for Childhood Cancer Research
Runner’s World
Salesforce.com
SanDisk Corporation
Sanofi-Aventis U.S. LLC
Sanofi-Aventis U.S. LLC PS Security Service Federal Credit Union
Silicon Valley Bank
Silicon Valley Community Foundation
SMART Modular Technologies
Spectrum Pharmaceuticals, Inc.
St. Joseph-Ogden High School Stater Bros. Charities
Terumo BCT

Deborah Tobias*
The Victor E. & Caroline E. Schutte Foundation - Trust E Vistar
VITAS Innovative Hospice Care Washington Gas
Yahoo!
Anonymous (3)

**$50,000 – $99,999**

Accenture
The A.G.E. Family Foundation
ADP
Air Products
Mabhubul Alam
Allstate Insurance Company
American Airlines
AMERICAN SYSTEMS
AutoCricket Corporation
AutoTrader.com
Bank of America
The Beck Family Foundation
Carol Lavin Bernick Family Foundation
Big Steaks Management, LLC
Blackstone Foundation
Janet & Alex Boggs*
Booz Allen Hamilton
British Columbia Lottery Corporation
Brooks-Mathews Foundation
BTIG
Becky & Dana Callow Family
Carol Lavin Bernick Family Foundation
Carlson Family Foundation, Inc.*
Cisco
Clear Channel Communications, Inc.
CN
Comcast Spotlight

Community Health Charities of Minnesota
Community Health Charities of New England
Credit Suisse
Doctor’s Choice Pharmacy
Dominick’s
DreamWorks Animation LLC
Ed Rachal Foundation
Englefield Oil Co.
Robert E. Gallagher Charitable Trust
GE Foundation
The Glass Family Foundation
Hamill Family Trust*
Hargrove
Leon W. (Pete) Harman
The HM Insurance Group
Hildegarde D. Becher Foundation
Human Genome Sciences, Inc.
Industrial Alliance Insurance and Financial Services, Inc.
Industrial Alliance Pacific (IAP)
Infor Global Solutions, Inc.
Jazz Pharmaceuticals plc*
John & Effie Speas Foundation
Kent Joshi*
Dan Kaplan
King & Spalding, LLP
Douglas Kroll Research Fund
Larson’s Charitable Foundation
Joyce Xavier Lennon
Tim Leslie
Lavin Family Foundation
Lighthouse Investment Partners, LLC
Marsh Supermarkets, Inc.
Menkes Developments Inc.
NARS
New York Community Bancorp
Northrop Grumman
Onyx Pharmaceuticals, Inc.
Padgett, Stratemann & Co., LLP
Parents Against Leukemia
Patrick Park
Party for a Cure
Phillips-Van Heusen Foundation Inc.
PhRMA
Ping Y. Tai Foundation
Donald Porteous
PRG
Rabobank
Ray Catena Auto Group
RMD Corporation
Ruth Robinson
Runners for Life, Houston
Salt River Pima-Maricopa Indian Community
Stephen Scherr
Seattle Genetics, Inc.
Sedano’s Supermarkets
The Sleep Family
Southern California Gas Company
Stonebridge Companies
SYNNEX Corporation
Target
Toy Brother’s Inc.
Total Wine & More
Toyota
Valenti Mid-Atlantic Management, LLC
Vanderbilt Sigma Chi
Walgreen Co.
Walmart Stores, Inc.
Washingtonian Magazine
Wells Fargo Foundation
WorldMark Family Foundation
Anonymous (1)

* Denotes multi-year commitment

---

**PHARMACEUTICAL FUNDING LEGEND**

- Patient Services/Education
- Public Policy
- Campaign
- Research
Anametrix, Inc.
Anadarko Petroleum Corporation
Ames True Temper
American Plant Insurance Company
American General Life & Accident
American Electric Systems
American Electric Power Resources LLC
American Direct Marketing
American Construction Co., Inc.
American Direct Marketing Resources LLC
American Electric Power
American Electric Systems
American Expiring Company
American General Life & Accident Insurance Company
American Plant
American TV & Appliance of Madison, Inc.
America's Charities
Ames True Temper
Anadarko Petroleum Corporation
Anametrix, Inc.
Madeline & Stephen Anbiner
Sandra & Noah Anderson
Anny Capital Management
Aning Johnson Company
Anunziata Sangiunetti Foundation
Anthem Blue Cross & Blue Shield
Anthem Blue Cross & Blue Shield of Ohio
Anybill
Apache Corporation
Area Property Partners &
Adler Realty Services
Argonne National Laboratory
Argy, Wiltse, & Robinson, P.C.
ARIAD Pharmaceuticals, Inc.
Jameson Arnold
Assurant
Assurant Foundation
Assurant Specialty Property
Assured Guaranty Ltd.
Astex Pharmaceuticals
AT&T
Athleta
Veronica Atkins
Audi North Atlanta
Augusta Oncology Associates
Avela Speciality Pharmacy
Baltimore Tour de Court in memory
of Rachel Minkove
Baptist Health South Florida
Ninne & John Barbey
BASF Corporation
Lee Bates
BB&T
BD - Accuri Cytometers
BD Biosciences
BDO USA, LLP
Beattie Homes Ltd.
Beckendorf Jr. High School
John Bellinger
The Belvedere Cove Foundation
The Benton Family
James Berger
Berkshire Bank
The Bernard McDonough
Foundation, Inc.
Bert Smith & Co.
Certified Public Accountants
Beta Engineering
Josh Billings - Freeze Your Lymphs Off
Alexandra Mayes Birnbaum
Bisnow
BJC Learning Institute
Blackdog Skeet Shoot
BlackRock Inc.
Blake Real Estate, Inc./
Bender Foundation, Inc.
Bloomberg
Blue Cross and Blue Shield
of Alabama
Blue Cross and Blue Shield
of Mississippi
Blue Cross Canada
Edward Blumenfeld
Blumenfeld Development Group
BMO Harris Bank
BMW of San Antonio
BNY Mellon
Steven Boal
Bruce Bocina
Robert Boliard
Bosco's Department Stores
Boston Millennia Partners
BP
BrassCraft
Brayton Purcell, LLP
Breeden-Adams Foundation
Brewers of Indiana Guild
Bridgestone Americas
Tire Operations
Briggs Equipment Services
Andrew Brock
Janice and Peter Brock
Melissa & Pierre Brondeau
Broward Health
The Brown Family
Frona A. Brown, EdD
Pamela & Morris Brown
Brown & Gould, LLP
Brown Mackie College
The Bryce Foundation
BuildASign.com
Dr. Mark Bullard
Becky & Jeff Burch
Burgin Roofing Services
Jan and Dr. Robert Burke
Burns & McDonnell Foundation
Butler Family Foundation
Lisa & Jeff Butts
Porter Byrum
C Kennedy and
Laura Baxter Foundation
C.H. Robinson Worldwide, Inc.
Caci, Inc.
Caisse Populaire Desjardins
Canadienne Italienne
Cambridge Major
Laboratories, Inc.
Caden Camens
Dillon Cameron
Cameron Hughes Wine
Matthew Campbell
Cancer Prevention Institute
of California
John Cannariato
Capital Health Plan
Capital One
Capital One Services, Inc. Canada
Capital File Magazine
Capstone Advisory Group
Cardinal Solutions Group LLC
Carella, Byrne, Cebicina, Olstein,
Brody & Agnello
CARFAX, Inc.
Carlos Batista Foundation
Carnival Cruise Lines
Cascades Recovery, Inc.
Catholic Health Partners/
Mercy Health
Catholic Health Services
Rita Cavanagh & Gerald Kafka
CBRE
CDW-G
Celator Pharmaceuticals
CenterPoint Energy
Central Texas Operators
Advertising Association, Inc.
Centro - Charleen's Angels
Cerner Corporation
CFACQ
Chambers Medical Foundation Tr.
Charity Buzz
Charity Dreams
Charles Moerlein Foundation,
Fifth Third Bank, Trustee
ChemWerth
The Cherry Picker Foundation
Chester Valley Golf Club
CHEVRON
Chiaramonte Construction
Company
Chicago Ambulatory Surgery
The Chicago Community
Foundation
Justin Cneh
City Barbeque
City of Batavia
Kathleen & Charles Clark
and Family
Susan & Jay Clark
Clark Construction Group LLC
Clark County Fire Department
Harland Clarke
Clayton Tile Distributing Co, Inc.
Cleary Gottlieb Steen & Hamilton
LLP
Isobel & Bruce Cieland
Fuly Clinkman, Jr.
Clifford Law Offices
The Clovis Castle
Clune Construction Company
CoActiv Capital Partners
The Cobb Foundation
Patrick Coffey
Cointar
Cole, Scott & Kissane P.A.
Color Me Rad 5K
The Colton Company
Columbia Yacht Club
Columns Resource
Group Foundation
Combined Health Agencies
Comcast
Commerce Bank
Community Foundation for
Southeast Michigan
Community Health Charities
of California
Community Health Charities
of Colorado
Community Health Charities
of Florida
Community Health Charities
of Iowa
Community Health Charities
of Kansas & Missouri
Community Health Charities
of the Southeast
Community Health Charities
of the Southeast
Community Health Charities
of Virginia
Compass Self Storage
Compatriot Capital, Inc.
Competitive Carriers Association
Contemporary Electrical Services, Inc.
Cook Children's
Health Care System
Cookie Associates, Ltd.
Cora and John H.
Davis Foundation
The CORE Training, Inc.
Corix Group of Companies
The Cornelles J. Coakley
Family Foundation Inc.
Shirley & William Comely
Ray Costa
Costco
Courtney Knight Gaines Foundation, Inc.
Covanta Energy Group
Covidien
Cracker Barrel
Crane Fund for Widows and Children
Cravath, Swaine & Moore LLP
Credit Suisse
Americas Foundation
Cross Country Consulting
Cruise Industry
Charitable Foundation
Cruise Planners/American Express
Crystal Trust
Jerry Cudzil
Janet Cuschiere
Custom Blenders Georgia, LLC
Custom Blenders Indiana, Inc.
Custom Blenders Missouri, Inc.
DaHunt for the Cure, LLC
Dana-Farber Cancer Institute
Danaher Foundation
Danford Foundation
Dante Consulting
Darcars Automotive Group
D’Arrigo Bros. Co.
Data Systems International
David & Justine Springberg Fund
Mr. and Mrs. Sami David
Al Davino
Leona & Donald Davis
The Davis Family Foundation
Davis Polk & Wardwell
Davis-Moore Auto Group
Deans Knight Capital Management Ltd.
Dear Jack Foundation
John Demaine
Denbury Resources Inc.
Steven DePrey
Detroit Auto Dealers Association
Deutsche Bank
Digitas
Dignity Health
Sam & John Dinos
Donald Dinsmore
Discount Tire Co.
Dixon Schwabl
DJO Global
DLA Piper LLP
Dodson Family Foundation
Brian Dohmen
Dominion Foundation
Dominion Mechanical Contractors, Inc.
Sean Dowd
DP-Master Manufacturing Co., Ltd.
DSE Hockey Club LP
Maxim Duckworth
Dunaways
Tom Dunham
Kyle Dutton
The Earl and Brenda Shapiro Foundation
East Tennessee Children’s Hospital
Deane Eastwood
eBioscience, Inc.
Eckert Seamans Cherin & Mellott LLC
Edgar A. Thronson Foundation
Edith M. Schweckendieck Trusts
Edward G. & Kathryn E. Mader Foundation
EFESTÉ Winery
eFleet Direct
Steven Eisenstadt
Israel Electric
The Eli & Edythe L. Broad Foundation
Eli Lilly and Company
elmwood Country Club
Emergent BioSolutions, Inc.
En Engineering, LLC
Encana Cares Foundation
The Enrichment Foundation
Entergy New Orleans, Inc.
Enterprise Holdings Foundation
Enterprise Rent-A-Car
EPR Properties
The Escher Foundation
ESPN980
EverydayFamily, Inc.
Ewie Co., Inc.
Express Scripts, Inc.
F.A.L.L. Classic
The Fairmont San Francisco
Faisal Rehman Medicine
Professional Corporation
Andres Fanjul
FarmerMac
Farms Group, Inc.
Eric Felder
Natalie Fernandez
Ferrari of San Francisco
Findlay Cadillac
Findlay Honda Henderson
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Mary Clare Finney
First NBC Bank
First Service Federal Credit Union
The Fledgling Fund
Fleet Lease Exchange Co. Inc.,
Flexco Fleet Services
Ian Fletcher
Florentine Caminisch Foundation
Florida Blue
Florida Cancer Specialists & Research Institute
Florida Panthers Foundation
FMC Corporation
Focus Diagnostics, Inc.
Foley & Larnder, LLP
Forestar Group, Inc.
Forza Resources
Fossil
Franklin American Mortgage Company
Geri and Dave Frantze
Freeport-McMoRan
Copper & Gold
Frickers
Howard Friend
Friends of LLS
Frieze Harley-Davidson
Froedtert & The Medical College of Wisconsin
FTI Consulting, Inc.
Fulbright & Jaworski LLP
Fundacion Segarra de Puerto Rico
Furniture Fair
G & T Orthopaedics and Sports Medicine
Enrico Gaglioti
Galaxie Solutions, Inc.
Galen College of Nursing
Israel Garcia
Gary P. Hall Endowment Fund
GE
GE Bright Lights
GE Capital
GEICO Philanthropic Foundation
Diane & Jay Geier
Generac Power Systems, Inc.
General Dynamics
General Motors Company
George and Mary Josephine Hammann Foundation
The George F. and Myra Shaskan Foundation,
Inc.
George L. Shields Foundation, Inc.
The Georgette Skellenger Trust
Georgia Regents University
Patricia & Christos Giannoulias
Gibson, Dunn & Crutcher, LLP
Gila River Casinos
Glimcher
Global Maintenance Consulting - Canada, Inc.
The Gold-Diggers, Inc.
Goldman Sachs
Goldman Sachs Matching Gift Program
Good Neighbor Pharmacy
Good Will Grill
Mr. and Mrs. John Goodish
Becky & Brett Gordon
Gosling’s Rum
The Grace J. Fippinger Foundation
Grainger, Inc.
David J. Grais
Grant Thornton LLP
Debbie & John Gray
Great American Insurance Group
Great Clips Calgary Coop
Greater Milwaukee Foundation, Inc.
Green Nature Marketing
Greenbrau Traurig, LLP
Gulf Coast Bank & Trust Company
Andrew F. Gulli
H. Lee Moffitt Cancer Center & Research Institute
Steven Haas
Halliburton
The Handlery Foundation
Elyahu Harari
Harkins Builders
Harrisburg Magazine
Harry Harrison & Amy Nauikas
The Harry & Jeanette Weinberg Foundation, Inc.
Harry C. Moores Foundation
The Hartley Company
Deane HASKIN
Hazmat Environmental Group, Inc.
The HCA Foundation
The HEADstrong Foundation
HEADstrong Lacrosse Club
H-E-B
Helen W. Bell Charitable Foundation
The Helis Foundation
Bruce J. Hendin
Henkel Consumer Goods, Inc.
Lisa & Garrett Herbert
Hegate Texas Properties
Highstar Capital
Al G. Hill, Jr.
Lyda Hill
Marcy & Donnie Hill
Hilton San Francisco
Hilton Worldwide
Hines Interests Limited Partnership
Hirestrategy
HITT Contracting, Inc.
Dave Hitz
Hockey Fights Cancer
Hogan Lovells US LLP
Holland Gregg IV Research Fund
HOLT CAT
HOT 99.5
Hotel Whitcomb
The Howard B. Bernick Foundation
Howard Family Foundation
Hoxworth Blood Center
HP
George Huang
Frieda & William Hunt
Huntington National Bank
Hy-Vee, Inc.
Hydraulic Supply Company
John Hyland
IBC Bank
IBM
ICAP Services North America, LLC
Incapital, LLC
Incyte Corporation
Independent Health
Indiana University Health
Infosys Public Services
Ingrams Foundation
Ingrams Foundation
* Denotes multi-year commitment
donors (continued)

Insulators International Health Hazard Fund
INTEGRIS Cancer Institute of Oklahoma
Intevac, Inc.
ISC Sales, LLC
I Supply Company
ITxM, The Institute for Transfusion Medicine
J H P Family Trust
J. Crew
J. Hamman Prime
J.B. Fuqua Foundation
J.T. Tai & Co Foundation, Inc.
Jackson Walker LLP
Chris Jacobs
JAE Credit Management LP
The Jake Wetchler Foundation
Kathy & Joel James
James L. Eichberg Foundation, Inc.
Jane and Frances Stein Foundation
Jarden Westchester Triathlon
Jared Coones Pumpkin Run
Jason’s Deli
JDP Mechanical, Inc.
Jeannette & H. Peter Kriendler Charitable Trust
Jefferys & Company, Inc.
Jenner & Block LLP
John Jerey
Jewish Federation of Palm Beach County
JFC Temps
The Jim Jacobs Charitable Foundation
The Jim Quay Memorial Fund
Jimmie B Golf Tournament
Jobson Sailing
John & Anna Sie Foundation
Johnson & Johnson
David Jones
Jordan Valley Medical Center
Joseph & Drenda Vijuk Foundation
Joseph R. Daly Foundation
JR Advanced Engineering
The June and Cecil McCole Charitable Fund
Kabam, Inc.
Kaiser Permanente
Susan & Daniel Kane
Kansas City Sports Commission
Susan Karches
Karen & Daniel Kosowsky Charitable Fund
Kass Family Foundation
Rochelle & Gary Katz
Ronald Katz
KBR, Inc.
KBR, Inc. Charitable Foundation
Kearney & Company
David Keeton
Kelly Integral Solutions, LLC
Ken Gardner Model Maker
Kent’s Run
KentuckyOne Health
Gloria & Richard Kerns
KeyBanc Capital Markets
Kforce Inc.
Kids ‘R’ Kids
Tim Kirby
Shelley & Chuck Kiven
Knock Out Cancer
Kohls
Kolache Factory
Koons Tysons Toyota
Adam Korn
Sharon Krany
Leslie Elliot Krause
Kritchman Family Foundation
The Kroger Co.
KST Data Inc.
L&L Paving Co., Inc.
Martin Labelle
David Labuda
Joseph Jacob
Ladish Co. Foundation
Kathy & Mike Ladra
LaFontaine Automotive Group
W. Robert Lappin
The Lappin Foundation
Latham & Watkins LLP
The Laverna Hahn Charitable Trust
Lavin Family Foundation
Learjet Employees Care Fund
Dan Lee
Left Hand Brewing Co.
Legacy Mutual Mortgage
Legal Placements, Inc.
Lehigh Valley Restaurant Group
Paul Leinwand
The Len-Ari Foundation, Inc.
Leon Medical Centers
Leon S. Peters Foundation
Lester & Edward Anixter Family Foundation
Levin Family Foundation
Brian Levine
Alyssa Lewandowski
Peggy & Jack Lewis
Steven Lieblich
Christine & Brad Lindquist
Lindquist Family Foundation
Ingrid & Jeff Lion Family
Jackeline & Dan Lion Family
The Lipman Family
LLS Maryland Chapter Journey of Hope Friends in honor of Dr. Judith E. Karp
LLS New York City Chapter Board of Trustees
LLS Silicon Valley & Monterey Bay Area Board of Trustees
Logistick, Inc.
Lois Pope Life Foundation
The Lotz Family Foundation
Lowell Homes
Paul Loyd
LSI Corporation
Sarah & Tami Luftby
Lumina Foundation
Lunardi’s Supermarket, Inc.
Lundbeck Canada, Inc.
M&T Bank
M7 Aerospace
Mack Madness, Inc.
Mackenzie Partners, Inc.
Macquarie
Macy’s, Inc.
Mike Mahlstedt
The Mammel Foundation
Manatt, Phelps & Phillips, LLP
Manhattan Associates
Mariner Real Estate Management
The Mark H. Zangmeister Center
Lois Markovich
Marsh & McLennan Companies
Roxanne & Rocco Martino
Marylo’s Coffee
The Mashkin Family Foundation
Maxim Group LLC
MAXIMUS Foundation
Helen & Danny Maxson
Mayo Clinic Arizona
Mayo Clinic Jacksonville
Michael McCaffrey
Mary E. McCaul
MCCI Group Holdings, LLC
MCCI Medical Group
Betsy & Brian McClure
McCown Gordon Construction, LLC
Marie McDemmond
McDermott, Will & Emery Charitable Foundation
McGladey LLP
Casey McGlynn
Patrick McGovern
The McNichols Family Foundation
Medley Capital
MedImmune, LLC
Megan’s Wings, Inc.
Saneeba & Sanjay Mehrotra
Melody’s Fund
The Memorial Foundation, Inc.
Memorial Healthcare System
MERCK & Co., Inc.
Merrill Lynch Wealth Management
The Meritor, Inc.
Merrill Lynch Wealth Management
Lance Meyerowitz
Lou Mezzo
Michael C. Fina
Michele Lunn Hope Foundation
Mick & Eileen Stout Foundation
Mid America Pathology Laboratory
Middleburg Wealth Management
Midwest Air Traffic Control
Midwestern Regional Medical Center
Mike Hunter’s Team
Milbank, Tweed, Hadley & McCloy LLP
Miles & Stockbridge PC
Robert Miller
Mindshare
Edward Miner
Suzy Minkoff
Hermé deWyman Miro
Missouri Foundation for Health
Mitsubishi Power Systems, Inc.
Lori Mody
Momentum Microsystems, Inc.
Monarch Beverage Company
Montgomery Inn at the Boathouse
The Moorings
Morgan Borsocz Consulting
Morgan Stanley
Morgan, Lewis & Bockius LLP
MorganFranklin Consulting
Morley
Gary Moy
MSC Industrial Supply Co.
Jill Mulvihill
Elizabeth & Frank Munger
Murphy-Hoffman Company
MUY Brands
MVHS Octagon Club
Names Family Foundation
Leslie & Larry Nance
Lanham Napier
National Cooperative Services Corporation
National Journal
National Philanthropic Trust
Nationwide Mutual Insurance Company
Amy Nauikas & Harry Harrison
The Nealon Family
NetApp
The Netter Foundation Inc.
New York State Laborers Health & Safety Trust
News Corporation Foundation
Nicholas Family Foundation
Nidec Motor Corporation
NMMA
Stacie Noel
Linda & Guy Nohra
Nolen Companies
Nordstrom
North Park Lincoln
North Sails
North Shore LU
Northern California Concierge Association
Northside Hospital
Northwestern Mutual
Norton Cancer Institute
Norton Healthcare
NOVA Home Loans
NPL Construction Company
Nuettaira Companies, LLC
O.C. Welch Ford
Ober Kaler
Lynne O’Brien
<table>
<thead>
<tr>
<th>Company/Institution</th>
<th>Contact Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peoples Natural Gas</td>
<td></td>
</tr>
<tr>
<td>Peppo</td>
<td></td>
</tr>
<tr>
<td>Performance Automotive Network</td>
<td></td>
</tr>
<tr>
<td>Performance Food Group</td>
<td></td>
</tr>
<tr>
<td>Pershing Square Foundation</td>
<td></td>
</tr>
<tr>
<td>Donita &amp; Sheldon Petersen</td>
<td></td>
</tr>
<tr>
<td>PGT Trucking, Inc.</td>
<td></td>
</tr>
<tr>
<td>The Phase Foundation</td>
<td></td>
</tr>
<tr>
<td>Thomas Philbrick</td>
<td></td>
</tr>
<tr>
<td>Phillips Hager &amp; North</td>
<td></td>
</tr>
<tr>
<td>Philadelphia Multiple Myeloma Networking Group</td>
<td></td>
</tr>
<tr>
<td>Piedmont Healthcare</td>
<td></td>
</tr>
<tr>
<td>Pinebridge Investments Ltd.</td>
<td></td>
</tr>
<tr>
<td>Pioneer Energy Services Corp.</td>
<td></td>
</tr>
<tr>
<td>Plaid Pantries, Inc.</td>
<td></td>
</tr>
<tr>
<td>Planned Systems International, Inc.</td>
<td></td>
</tr>
<tr>
<td>Pleasantville Road Partners</td>
<td></td>
</tr>
<tr>
<td>PNC Bank</td>
<td></td>
</tr>
<tr>
<td>PNC Financial Services Group</td>
<td></td>
</tr>
<tr>
<td>Polk Brothers Foundation</td>
<td></td>
</tr>
<tr>
<td>Polisnelli PC</td>
<td></td>
</tr>
<tr>
<td>Popotent Inc.</td>
<td></td>
</tr>
<tr>
<td>Popular Community Bank</td>
<td></td>
</tr>
<tr>
<td>Porter B. Byrum Charitable Trust</td>
<td></td>
</tr>
<tr>
<td>Powell Industries</td>
<td></td>
</tr>
<tr>
<td>Prairie Meadows</td>
<td></td>
</tr>
<tr>
<td>The Pray Family Foundation</td>
<td></td>
</tr>
<tr>
<td>Monika &amp; John Preston</td>
<td></td>
</tr>
<tr>
<td>Price Chopper Supermarkets</td>
<td></td>
</tr>
<tr>
<td>Progressive Community Management, Inc.</td>
<td></td>
</tr>
<tr>
<td>Proskauer Rose LLP</td>
<td></td>
</tr>
<tr>
<td>Purdue Pharma L.P.</td>
<td></td>
</tr>
<tr>
<td>The PV Bike Chicks along with Nancy &amp; Dave Dicario</td>
<td></td>
</tr>
<tr>
<td>Quest Diagnostics</td>
<td></td>
</tr>
<tr>
<td>Quinn Roofing Solutions Inc.</td>
<td></td>
</tr>
<tr>
<td>Quiznos</td>
<td></td>
</tr>
<tr>
<td>RaceMenu</td>
<td></td>
</tr>
<tr>
<td>Rahr Malting Co.</td>
<td></td>
</tr>
<tr>
<td>Ralph H. &amp; Ruth J. McCullough Foundation</td>
<td></td>
</tr>
<tr>
<td>Ralph Lauren</td>
<td></td>
</tr>
<tr>
<td>RBC Capital Markets Corporation</td>
<td></td>
</tr>
<tr>
<td>RCC Liquidation Trust</td>
<td></td>
</tr>
<tr>
<td>Real Estate One Foundation</td>
<td></td>
</tr>
<tr>
<td>Red Robin</td>
<td></td>
</tr>
<tr>
<td>Redwood Regional Medical Group</td>
<td></td>
</tr>
<tr>
<td>Reece Holbrook Win Anyway Foundation, Inc.</td>
<td></td>
</tr>
<tr>
<td>Regence BlueShield of Idaho</td>
<td></td>
</tr>
<tr>
<td>Reliable Churchill, LLLP</td>
<td></td>
</tr>
<tr>
<td>Reliant Energy</td>
<td></td>
</tr>
<tr>
<td>Brenda &amp; Paul Remark</td>
<td></td>
</tr>
<tr>
<td>Trish &amp; Richard Rendina</td>
<td></td>
</tr>
<tr>
<td>Rerum Noruvam Charitable Trust</td>
<td></td>
</tr>
<tr>
<td>Resolution Run to Kick Cancer</td>
<td></td>
</tr>
<tr>
<td>Nicole Restrepo</td>
<td></td>
</tr>
<tr>
<td>The Rhoda and David Chase Family Foundation, Inc.</td>
<td></td>
</tr>
<tr>
<td>Riemer &amp; Braunstein LLP</td>
<td></td>
</tr>
<tr>
<td>RiverView Shopping Center</td>
<td></td>
</tr>
<tr>
<td>RoadID, Inc.</td>
<td></td>
</tr>
<tr>
<td>Robert A. and Gloria Sherman Foundation</td>
<td></td>
</tr>
<tr>
<td>The Robert H. Lyon</td>
<td></td>
</tr>
<tr>
<td>Leukemia Foundation</td>
<td></td>
</tr>
<tr>
<td>The Roderick Seward, Flossie Radcliffe &amp; Helen M. Galloway Foundation</td>
<td></td>
</tr>
<tr>
<td>Nancy &amp; Richard Rogers</td>
<td></td>
</tr>
<tr>
<td>Rogers Family Foundation</td>
<td></td>
</tr>
<tr>
<td>Rollin M. Gerstacker Foundation</td>
<td></td>
</tr>
<tr>
<td>Roma Charitable Foundation</td>
<td></td>
</tr>
<tr>
<td>Rosemary Quinian Kelly Foundation</td>
<td></td>
</tr>
<tr>
<td>Lois &amp; Jerry Rosenblum</td>
<td></td>
</tr>
<tr>
<td>Lindsay Rosenwald</td>
<td></td>
</tr>
<tr>
<td>Rossman, Hurt, Hoffman, Inc.</td>
<td></td>
</tr>
<tr>
<td>Ross, Swadling, H.</td>
<td></td>
</tr>
<tr>
<td>Rossman, Hurt, Hoffman, Inc.</td>
<td></td>
</tr>
<tr>
<td>RPA Advisors LLC</td>
<td></td>
</tr>
<tr>
<td>Joan &amp; Paul Rubschlager</td>
<td></td>
</tr>
<tr>
<td>The Running Zone Foundation</td>
<td></td>
</tr>
<tr>
<td>S.F. Navigatour, Inc.</td>
<td></td>
</tr>
<tr>
<td>SAC N PAC</td>
<td></td>
</tr>
<tr>
<td>Safety-Kleen Systems, Inc.</td>
<td></td>
</tr>
<tr>
<td>The Safeway Foundation</td>
<td></td>
</tr>
<tr>
<td>SAIC</td>
<td></td>
</tr>
<tr>
<td>Sail America</td>
<td></td>
</tr>
<tr>
<td>Sailing for a Cure Foundation</td>
<td></td>
</tr>
<tr>
<td>Sailing World</td>
<td></td>
</tr>
<tr>
<td>Lauren &amp; John Salata</td>
<td></td>
</tr>
<tr>
<td>Salesforce.com Foundation</td>
<td></td>
</tr>
<tr>
<td>David Salinas</td>
<td></td>
</tr>
<tr>
<td>Salisbury Men's Lacrosse</td>
<td></td>
</tr>
<tr>
<td>SallieMae</td>
<td></td>
</tr>
<tr>
<td>Sam J. Frankino Foundation</td>
<td></td>
</tr>
<tr>
<td>Sam Swope Auto Group, LLC</td>
<td></td>
</tr>
<tr>
<td>Samuel C. Cantor Charitable Trust</td>
<td></td>
</tr>
<tr>
<td>Samuel P. Mandell Foundation</td>
<td></td>
</tr>
<tr>
<td>San Diego Padres</td>
<td></td>
</tr>
<tr>
<td>San Francisco Travel</td>
<td></td>
</tr>
<tr>
<td>Sap America, Inc.</td>
<td></td>
</tr>
<tr>
<td>Sarver Charitable Trust</td>
<td></td>
</tr>
<tr>
<td>Barbara Saulnier</td>
<td></td>
</tr>
<tr>
<td>Savannah Chatham Imaging LLC</td>
<td></td>
</tr>
<tr>
<td>Bradley Scher</td>
<td></td>
</tr>
<tr>
<td>Susan &amp; Michael Schulides</td>
<td></td>
</tr>
<tr>
<td>Schwabe Charitable Fund</td>
<td></td>
</tr>
<tr>
<td>Schwabe Williamson &amp; Wyatt, PC</td>
<td></td>
</tr>
<tr>
<td>Mike Schwab</td>
<td></td>
</tr>
<tr>
<td>Scott Schweighauser</td>
<td></td>
</tr>
<tr>
<td>Helen &amp; Stormy Scott</td>
<td></td>
</tr>
<tr>
<td>Scott Kennedy Maritime Art</td>
<td></td>
</tr>
<tr>
<td>Scott Safety</td>
<td></td>
</tr>
<tr>
<td>SDG&amp;E</td>
<td></td>
</tr>
<tr>
<td>Seattle Cancer Care Alliance</td>
<td></td>
</tr>
<tr>
<td>SEFCU</td>
<td></td>
</tr>
<tr>
<td>Isador S. Segall Trust</td>
<td></td>
</tr>
<tr>
<td>Seminole Tribe of Florida</td>
<td></td>
</tr>
<tr>
<td>Sempra Employee Giving Network</td>
<td></td>
</tr>
<tr>
<td>Sempra Energy Foundation</td>
<td></td>
</tr>
<tr>
<td>Semnabogen LLC</td>
<td></td>
</tr>
<tr>
<td>Sessions, Fishman, Nathan &amp; Israel, LLC</td>
<td></td>
</tr>
<tr>
<td>Carl Sewell</td>
<td></td>
</tr>
<tr>
<td>The Shawn Sullivan Charitable Fund</td>
<td></td>
</tr>
<tr>
<td>Sherrard Kuzz LLP</td>
<td></td>
</tr>
<tr>
<td>Shield-Ayres Foundation</td>
<td></td>
</tr>
<tr>
<td>Diana &amp; Steve Shields</td>
<td></td>
</tr>
<tr>
<td>The Shimin Foundation</td>
<td></td>
</tr>
<tr>
<td>Shiseido Americas Corporation</td>
<td></td>
</tr>
<tr>
<td>Shook, Hardy &amp; Bacon LLP</td>
<td></td>
</tr>
<tr>
<td>ShopRite</td>
<td></td>
</tr>
<tr>
<td>Sidley Austin LLP</td>
<td></td>
</tr>
<tr>
<td>The Sidney, Milton &amp; Leoma Foundation</td>
<td></td>
</tr>
<tr>
<td>Simon Foundation</td>
<td></td>
</tr>
<tr>
<td>Siemens</td>
<td></td>
</tr>
<tr>
<td>Josh Sigman</td>
<td></td>
</tr>
<tr>
<td>Julie E. Silcock &amp; Houlihan Lokey</td>
<td></td>
</tr>
<tr>
<td>John Silvestri</td>
<td></td>
</tr>
<tr>
<td>Simmonds Family Foundation</td>
<td></td>
</tr>
<tr>
<td>Gilbert Simonetti III</td>
<td></td>
</tr>
<tr>
<td>Stichin Foundation Inc.</td>
<td></td>
</tr>
<tr>
<td>Sue Sitterman Team</td>
<td></td>
</tr>
<tr>
<td>Skadden, Arps, Slate, Meagher &amp; Flom, LLP</td>
<td></td>
</tr>
<tr>
<td>Slice of Lime Foundation</td>
<td></td>
</tr>
<tr>
<td>Cheryl Smelt</td>
<td></td>
</tr>
<tr>
<td>Elaine Smith</td>
<td></td>
</tr>
<tr>
<td>Elizabeth Fago Smith</td>
<td></td>
</tr>
<tr>
<td>Phyllis &amp; Douglas A. Smith</td>
<td></td>
</tr>
<tr>
<td>SoftLayer Technologies, Inc.</td>
<td></td>
</tr>
<tr>
<td>Sonepar, USA</td>
<td></td>
</tr>
<tr>
<td>Southeast Nebraska Cancer Center</td>
<td></td>
</tr>
<tr>
<td>Southport Bank</td>
<td></td>
</tr>
<tr>
<td>Spanos</td>
<td></td>
</tr>
<tr>
<td>Spire</td>
<td></td>
</tr>
<tr>
<td>Carol &amp; Mark Spisak</td>
<td></td>
</tr>
<tr>
<td>The Springfield Foundation</td>
<td></td>
</tr>
<tr>
<td>Sprint</td>
<td></td>
</tr>
<tr>
<td>Sprint Center/AGS</td>
<td></td>
</tr>
<tr>
<td>SRA International Corp.</td>
<td></td>
</tr>
<tr>
<td>St. Francis Health - IBM</td>
<td></td>
</tr>
<tr>
<td>St. Joseph's/Candler</td>
<td></td>
</tr>
<tr>
<td>St. Juste Management Corp.</td>
<td></td>
</tr>
<tr>
<td>St. Luke's Mountain States Tumor Institute</td>
<td></td>
</tr>
<tr>
<td>Shannon Stafford</td>
<td></td>
</tr>
<tr>
<td>Stanley Korshak</td>
<td></td>
</tr>
<tr>
<td>Starbucks Corporation</td>
<td></td>
</tr>
<tr>
<td>State Street Corporation</td>
<td></td>
</tr>
<tr>
<td>Steptoe &amp; Johnson LLP</td>
<td></td>
</tr>
<tr>
<td>Stinson Morrison Hecker LLP</td>
<td></td>
</tr>
<tr>
<td>Brian Stoffers</td>
<td></td>
</tr>
<tr>
<td>Stride Rite Philanthropic Foundation</td>
<td></td>
</tr>
<tr>
<td>Steven Strulowitz</td>
<td></td>
</tr>
<tr>
<td>Sugar Creek Packing Co.</td>
<td></td>
</tr>
<tr>
<td>Sully's Bar &amp; Grill</td>
<td></td>
</tr>
<tr>
<td>SunDun Office Refreshments</td>
<td></td>
</tr>
<tr>
<td>Sunesis Pharmaceuticals, Inc.</td>
<td></td>
</tr>
<tr>
<td>SunTrust Banks, Inc.</td>
<td></td>
</tr>
<tr>
<td>SunTrust Banks, Inc.</td>
<td></td>
</tr>
<tr>
<td>SunUrgentCare</td>
<td></td>
</tr>
<tr>
<td>SurfiTec</td>
<td></td>
</tr>
<tr>
<td>Sutphin Family Foundation</td>
<td></td>
</tr>
<tr>
<td>Sutter Health Sacramento Sierra Region</td>
<td></td>
</tr>
<tr>
<td>Swanson Group, Ltd.</td>
<td></td>
</tr>
<tr>
<td>Elizabeth &amp; Michael Sweeney</td>
<td></td>
</tr>
<tr>
<td>Michael Sweig</td>
<td></td>
</tr>
<tr>
<td>Sysmex America, Inc.</td>
<td></td>
</tr>
<tr>
<td>Sheri Tackett</td>
<td></td>
</tr>
<tr>
<td>Talon Therapeutics</td>
<td></td>
</tr>
<tr>
<td>TAXI, Inc.</td>
<td></td>
</tr>
<tr>
<td>TCDI</td>
<td></td>
</tr>
<tr>
<td>TD Bank</td>
<td></td>
</tr>
<tr>
<td>Team Survivor</td>
<td></td>
</tr>
<tr>
<td>Team TELUS Cares</td>
<td></td>
</tr>
<tr>
<td>Team Todd Memorial Research Fund</td>
<td></td>
</tr>
<tr>
<td>Telstra Global</td>
<td></td>
</tr>
<tr>
<td>Teneo Strategy</td>
<td></td>
</tr>
<tr>
<td>Carole Teter</td>
<td></td>
</tr>
<tr>
<td>Thacker Martinsek LPA</td>
<td></td>
</tr>
<tr>
<td>Billie Thomas</td>
<td></td>
</tr>
<tr>
<td>Judy &amp; Michael Thomas</td>
<td></td>
</tr>
<tr>
<td>Thomas and Agnes</td>
<td></td>
</tr>
<tr>
<td>Carvel Foundation</td>
<td></td>
</tr>
<tr>
<td>The Thomas M. &amp; Irene B. Kirbo Charitable Foundation</td>
<td></td>
</tr>
<tr>
<td>Thompson Habib Denison (THD)</td>
<td></td>
</tr>
<tr>
<td>* Denotes multi-year commitment</td>
<td></td>
</tr>
</tbody>
</table>
Tiber Creek Partners LLC
Title Associates
TJX Companies, Inc.
Suzanne & Robert Tomsich
Toole-Ghianni Family Fund
Toyota Dealer Match Program
Transwestern
Travelzoo Inc.
TRC Operating Company
Trion Group, Inc.
Angela & Gary Trovato
TRUIST
Trust Company of the South
Try Team
Eddy Tsang
Man Chung Tsang
Jane & Robert Tschudy
Tube City IMS
Tulsa Expo Center
Turner Construction
Turner Foundation Inc.
Jack A. Turpin
Nat Tyce
UA Liquidating Trust
UBS Financial Services
UBS O’Connor LLC
UC San Diego/Sharp
BMT Program
UH
Ultimate Software
UNC Health Care & Rex Healthcare
Unigen
Union First Market Bank
Union Pacific Corp. Fund for Effective Government
United States Marine, Inc.
United States Steel Corporation
United States Steel Corporation - Mon Valley Works
The University of Kansas Cancer Center
UPMC
UPS
US Sailing
Valero Energy Corporation
Frank Van Zon
VCU Health System
Vencello Group, Inc.
Kathryn & Leo Vencello, Jr.
Phil Venables
Venari Resources LLC
Verizon
Frank Vero
Vetoquinol
Viacom Inc.
The Victor E. & Caroline E. Schute Foundation - 1959
Volkswagen Group of America, Inc
Volunteer Kansas, Inc.
VSP Global
W.B. Engineering & Consulting PLLC
The W. O’Neil Foundation
Waller Lansden Dortch & Davis LLP
Walmart Foundation
Paula Wardynski
Warrenvhoen Family Foundation
Warner Pacific
WASH-FM
Washington Business Journal
Watkins Meegan LLC
Wawa, Inc.
Wawanessa Insurance
WBIG
WebMD Health Foundation, Inc.
Wechsler/Marsico Associates
Weldon Service & Repair
Karlie Wells
West Marine
West-Ward Pharmaceuticals
Wet Willies Management Corp.
White Castle
The William Carter Company
Wallace Williams
Williams & Connolly LLP
Winnipeg Group Holdings
Winston & Strawn LLP
Winston Partners Group, LLC
WVIB-TV
WZMQ
The Woolley Family
WTOP Radio
WUSA9
Daniel Wyner
Eric, Tamara and Nicholas Yollick
Young Hearts
Youthland Academy
Drs. Adelaide & John Zabriskie
Zolkiewski Patent Solutions Group, SC
Joseph Zvesper
Anonymous (21)

**TOP CAMPAIGN FUNDRAISERS**

Schools that have raised more than $25,000, individuals who have raised more than $50,000 or companies/teams that have raised more than $100,000 to support LLS’s mission.

**ADP**
Dinamari Alcuni
Ally’s Army & Caulin’s Crew
Matt Andrekovich
Alexandra “Alix” Arguelles
Alex Alli
Astella Pharmaceuticals
John Atwood
Austaco, Ltd.
Baker Botts
Katherine Baltren
Bank of America
Baptist Health South Florida
Barclays
Cody Barnes
Barbara Bernick*
Ellen Bettridge
Carrie Billick
Biogen Idec
The Blackstone Group
Bradley Blanken
Brad Blumenfeld
BMC
AJ Boddin
Joe Bouigny
Jim Brandell
James D. Burgess
Burlington
CA Technologies
Brian Campbell
Chris Campbell
Cancer Crushers of South Florida
Robert “Spider” Cantley
Steven Cantrell
Carter’s Inc.
Celgene Corporation
CenturyLink
Steve Chen
Chris’ Wish
Deborah Christine
Citrix Systems, Inc.
Molly Clark
Stephanie Clarkson
Coach, Inc.
Kimberly Kranys Cobb
Matt Cohoat
Bruce Collins
Tim Cook
Ashley Cop
Lori Cordano
Spencer Cox
Cricket Communications, Inc.
Paula Dagen
Amy DeCosmo
Stacey Deere
Deloitte LLP
Meggie Dials
Emily Dickinson
Scott Dinsmore
Carolyn Dodson
Brian Dohmen
Christian Dooij
Walker Durant
Patricia Eaves de Pagan
Dan Eckerd
Daniel Edelen*
Elbit Systems of America
Dr. Ahmad Emami
Ernst & Young LLP
Randy Everett
Julia Luros Failey
Renee Lebas
Ryan LaFontaine
Rudy LeBlanc
Michael Lechtenberg
Justin Legg
Mark Lindquist
Brandy Liss

* Denotes multi-year commitment

**PHARMACEUTICAL FUNDING LEGEND**
- Patient Services/Education
- Public Policy
- Campaign
- Research

28
Joshua Lite
The Lymphomaniacs
Mike Mahstedt
Tre Mantuano
Regina Martin
Erica Melone
Tom McCord
Tim McCormick Memorial
Ursula McIntyre
James Mezir, MD
Lance Meyerovich
Microsoft
Stacey Mikel
Millennium: The Takeda Oncology Company
Robert Miller
Moms In Training
Mike Montarbo
Alyssa Morteo
Adam Mott
Mt. Pisgah School
Blaine Muhi
Roxana Muzzammel
NARS
Lynne O’Brien
The Olive Garden
Italian Restaurant
Craig Ortego
Jessica Outer
Peach Pagano
Blaine Palmer
Joe Parisi
Thomas Parseghian
Partners For A Cure
Pfizer, Inc.
Lauren Plichta
Angela Poliskey
PricewaterhouseCoopers LLP
PVH
Megan Quall
Quintiles
Sarah Ray
David Reich
Christina Resasco
Riders of the Storm
Rebekah Riemer
Sondra Rose
Roswell North High School
Karen Routt
Jason Ryan
Les Sachanowicz
Salesforce.com
Dr. Larry Saltzman
SanDisk Corporation
Beth Schrader
Scott Savacool
Scott Schweighauser
Glenn Scott
Security Service
Federal Credit Union
Bryce Seki
Coty Sensabaugh
C. Kevin Shannahan
Leslie Sharp
Patty Sharpe
Lorraine Shea
Jill Shimp
The Shinsky Family
Josh Sigman
Silicon Valley Bank
Anna Dudenhoefner Simpson
Stacy Simpson
Skippy’s Team 3.0
Angie Sly
SMART Modular Technologies
Jeremy Smith
Joseph Solimini, Sr.
Tony Sorrentino
Stater Bros. Charters
Stick It 2 Cancer
Daneen & Charles Stiefel
Diana & Todd Stiefel
Randy Stokes
Emily Szaferski
Team 2 Degrees
Team 40 For A Cure
Team Alex
Team Blumenfeld & Team Waterman
Team Brenna
Team Jackie
Team PhRMA
Team Runnin’ For A Reason
Team Shannon
Team WillyK
Fran Templin
Terumo BCT
Teva Oncology
Scott Thomas
In memory of Jerry Throgmartin
Linda Price Topp
Gloria Torres
Dorothy Trainer
Tu Tran
Brett Tremain
Leo Tucker
United Launch Alliance
Ryan Van Pelt
Vistar
VITAS Innovative Hospice Care
Waddell & Reed
Walt Whitman High School
Walter Johnson High School
Brian S. Waterman
Watertown Middle School
Lisette Watters
Wells Fargo
Mary Jo White
Mary Whelan-Levine
Brittany Wilbur
William Mason High School
Keith Williams
Jennifer Willoughby
Yahoo!
Brian Zettler
Steven Ziff
Samantha Zullo
Legacy Circle honors those who designate LLS as a beneficiary of their will, trust, retirement account or insurance policy, or fund a charitable gift annuity. We list our newest members below along with those whose bequests of $10,000 or more were received this year.
Rose Accardi*
Louis R. Albrecht
Hector Alfonso*
Kenneth Balbo*
Leota Bay*
Florence Bevan*
Hannah Blum
Margaret Boryan*
Roger Busch*
Doy Caga
Kirk and Jessica Cassidy
Grace Chui-Miller
Wayne and Mary Clark*
Nellie Couwenhoven*
Winifred DaVIA*
Martha DeMeezer
Shirley Dennie*
Deborah Diamond
Susan Dick
Peggy and Margaret Dupaquier*
Carol Torra Edwards*
Peggy Ellerston
Jerome and Patricia Fehribach
Robert Foster
Isabel Gardner*
Grace Garza
David Gelman*
Lydia Ghigliotti*
Nancy Gold
Linda Goto*
Carol Gottlieb
Kathleen Grega*
Daniel and Jennifer Greyber
Jane Handley*
William Hartz
Judith Heifant*
Magnus and Juanita Heubi*
Stephen Higgs
Edith Ingram*
Sandra Janzen*
Suzanne Kelly
Amelia Kelly*
Anne Kilgrew
Joan Kotran
Philip Kozlowski
Arthur F. Krueger, Jr.
Reverend Jerry Kuehn
Margaret W. Lawrence
Wallace Blaine Lawrence*
Jean Leinbach*
Margaret Levy
Marguerite Liesch*
Rose Lightfoot*
Robert Lipka, DDS
Helen Lippert*
Kathryn Lynott
Angela Manns*
Jack Marcus*
Piper Medcalf
Arvin Miller*
Veronica Moskewicus*
Maxine Murray*
Mary Jean Neal*
Barbara Nelson*
James Osterburg, PhD
Margaret Patterson*
John Pickles*
Gretchen Pressburg
Mary Richardson*
Anisa Robinson
Ed Rodbro
Isadore Sacks*
Violaine Sands
Jane Siegel*
Isabel M. Schultz*
Harold and Phyllis Schwend*
Barry and Sheila Scott
Faith Ann Searle*
Gail Secrist*
Bruno and Irma Selmi*
Harriet Share*
Richard Silley
Mary Smith*
Inez Starr*
Anna Stojanovich*
Betty Strucker*
Bruce Swartz*
Al Sweigert
Jeffrey Tarte*
James Tobler
Diego Tobon
Nancy Travis*
Harriet Troyan*
Benedict and Christa VanderLinden*
John Walter
Gerald Wellick*
Chris Williams
Stella Yusko*
Anonymous (6)
The Board of Directors
The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated financial statements of The Leukemia & Lymphoma Society, Inc. (LLS), which comprise the consolidated balance sheet as of June 30, 2013, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements.

**Management’s Responsibility for the Financial Statements:** Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

**Auditors’ Responsibility:** Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the organization’s preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the organization’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

**Opinion:** In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2013, and the changes in its net assets and its cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.

**Report on Summarized Comparative Information:** We have previously audited LLS’s consolidated financial statements, and we expressed an unmodified opinion on those audited consolidated financial statements in our report dated September 21, 2012. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2012 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

KPMG LLP
September 18, 2013
New York, NY
## Consolidated Balance Sheet

The Leukemia & Lymphoma Society, Inc. / June 30, 2013 (With comparative amounts at June 30, 2012) (In thousands)

### Assets

<table>
<thead>
<tr>
<th>Description</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents (note 6)</td>
<td>$27,300</td>
<td>$25,972</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>5,555</td>
<td>6,716</td>
</tr>
<tr>
<td>Legacies and contributions receivable, net (note 5)</td>
<td>8,026</td>
<td>5,413</td>
</tr>
<tr>
<td>Investments (notes 3 and 6)</td>
<td>190,555</td>
<td>184,084</td>
</tr>
<tr>
<td>Fixed assets, net (note 7)</td>
<td>10,853</td>
<td>6,854</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>$242,289</td>
<td>$229,039</td>
</tr>
</tbody>
</table>

### Liabilities and Net Assets

#### Liabilities:

<table>
<thead>
<tr>
<th>Description</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$21,388</td>
<td>$20,196</td>
</tr>
<tr>
<td>Deferred revenue (note 6)</td>
<td>35,074</td>
<td>17,737</td>
</tr>
<tr>
<td>Grants payable (note 2)</td>
<td>82,062</td>
<td>73,966</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td>138,524</td>
<td>111,899</td>
</tr>
</tbody>
</table>

#### Commitments and contingencies (notes 2 and 9)

<table>
<thead>
<tr>
<th>Description</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net assets (note 4):</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted</td>
<td>91,217</td>
<td>101,620</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>9,105</td>
<td>12,163</td>
</tr>
<tr>
<td>Permanently restricted</td>
<td>3,443</td>
<td>3,357</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td>103,765</td>
<td>117,140</td>
</tr>
</tbody>
</table>

### Total liabilities and net assets

<table>
<thead>
<tr>
<th>Description</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td>$242,289</td>
<td>$229,039</td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
### Revenue

<table>
<thead>
<tr>
<th>Description</th>
<th>Unrestricted</th>
<th>Temporarily restricted</th>
<th>Permanently restricted</th>
<th>Total 2013</th>
<th>Total 2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Campaign contributions</td>
<td>$261,258</td>
<td>$14,840</td>
<td>$—</td>
<td>$276,098</td>
<td>$275,812</td>
</tr>
<tr>
<td>Less direct donor benefit costs</td>
<td>(35,510)</td>
<td>—</td>
<td>—</td>
<td>(35,510)</td>
<td>(39,173)</td>
</tr>
<tr>
<td>Net campaign contributions</td>
<td>225,748</td>
<td>14,840</td>
<td>—</td>
<td>240,588</td>
<td>236,639</td>
</tr>
<tr>
<td>Co-pay contributions</td>
<td>—</td>
<td>48,143</td>
<td>—</td>
<td>48,143</td>
<td>54,600</td>
</tr>
<tr>
<td>Legacies</td>
<td>3,715</td>
<td>511</td>
<td>—</td>
<td>4,226</td>
<td>5,049</td>
</tr>
<tr>
<td>Donated services and media (note 6)</td>
<td>7,750</td>
<td>—</td>
<td>—</td>
<td>7,750</td>
<td>5,328</td>
</tr>
<tr>
<td>Net interest and dividend income</td>
<td>1,925</td>
<td>124</td>
<td>26</td>
<td>2,075</td>
<td>2,152</td>
</tr>
<tr>
<td>Net increase (decrease) in fair value of investments (note 3)</td>
<td>9,281</td>
<td>348</td>
<td>60</td>
<td>9,689</td>
<td>(155)</td>
</tr>
<tr>
<td>Grant refunds</td>
<td>1,844</td>
<td>—</td>
<td>—</td>
<td>1,844</td>
<td>1,477</td>
</tr>
<tr>
<td>Net assets released from restrictions:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-pay assistance</td>
<td>42,650</td>
<td>(42,650)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Satisfaction of other donor restrictions</td>
<td>24,374</td>
<td>(24,374)</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Total revenue</strong></td>
<td>317,287</td>
<td>(3,058)</td>
<td>86</td>
<td>314,315</td>
<td>305,090</td>
</tr>
</tbody>
</table>

### Expenses (note 10)

**Program services:**

- Research                                         | 79,234       | —                      | —                      | 79,234     | 73,512     |
- Patient and community service                     | 117,769      | —                      | —                      | 117,769    | 115,727    |
- Public health education                            | 47,875       | —                      | —                      | 47,875     | 44,772     |
- Professional education                            | 9,330        | —                      | —                      | 9,330      | 8,785      |
| **Total program services**                         | 254,208      | —                      | —                      | 254,208    | 242,796    |

**Supporting Services:**

- Management and general                            | 27,258       | —                      | —                      | 27,258     | 24,869     |
- Fundraising                                       | 46,140       | —                      | —                      | 46,140     | 43,557     |
| **Total supporting services**                      | 73,398       | —                      | —                      | 73,398     | 68,426     |

**Total expenses**                                  | 327,606      | —                      | —                      | 327,606    | 311,222    |

**Change in net assets before foreign currency translation adjustment**

- (10,319)                                           | (3,058)      | 86                     | —                      | (13,291)   | (6,132)    |

**Foreign currency translation adjustment**

- (84)                                               | —            | —                      | —                      | (84)       | (133)      |

**Change in net assets**                             | (10,403)     | (3,058)                | 86                     | (13,375)   | (6,265)    |

### Net Assets

<table>
<thead>
<tr>
<th>Description</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning of year</td>
<td>101,620</td>
<td>117,140</td>
</tr>
<tr>
<td>End of year</td>
<td>91,217</td>
<td>103,765</td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
## Supporting Services

### Total Program Services

<table>
<thead>
<tr>
<th>Item</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>$58,899</td>
<td>$54,527</td>
</tr>
<tr>
<td>Patient and community service</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Public health education</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Professional education</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>$58,899</td>
<td>$54,527</td>
</tr>
<tr>
<td>Management and general</td>
<td>$27,258</td>
<td>$31,222</td>
</tr>
<tr>
<td>Fundraising</td>
<td>$25,400</td>
<td>$20,106</td>
</tr>
<tr>
<td>Total</td>
<td>$27,258</td>
<td>$31,222</td>
</tr>
</tbody>
</table>

### Direct Donor Benefit Costs

<table>
<thead>
<tr>
<th>Item</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>$27,258</td>
<td>$31,222</td>
</tr>
</tbody>
</table>

### Expenses

#### Research

<table>
<thead>
<tr>
<th>Item</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient and community service</td>
<td>$58,899</td>
</tr>
<tr>
<td>Public health education</td>
<td></td>
</tr>
<tr>
<td>Professional education</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>$58,899</td>
</tr>
</tbody>
</table>

#### Patient and Community Service

<table>
<thead>
<tr>
<th>Item</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Public health education</td>
<td></td>
</tr>
<tr>
<td>Professional education</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
</tr>
</tbody>
</table>

#### Public Health Education

<table>
<thead>
<tr>
<th>Item</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professional education</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
</tr>
</tbody>
</table>

#### Professional Education

<table>
<thead>
<tr>
<th>Item</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td></td>
</tr>
</tbody>
</table>

#### Total Program Services

<table>
<thead>
<tr>
<th>Item</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>24.2%</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>36.0%</td>
</tr>
<tr>
<td>Public health education</td>
<td>14.6%</td>
</tr>
<tr>
<td>Professional education</td>
<td>2.8%</td>
</tr>
<tr>
<td>Total</td>
<td>77.6%</td>
</tr>
</tbody>
</table>

#### Management and General

<table>
<thead>
<tr>
<th>Item</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>8.3%</td>
</tr>
</tbody>
</table>

#### Fundraising

<table>
<thead>
<tr>
<th>Item</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>14.1%</td>
</tr>
</tbody>
</table>

#### Total Support Services

<table>
<thead>
<tr>
<th>Item</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>22.4%</td>
</tr>
<tr>
<td>Patient and community service</td>
<td></td>
</tr>
<tr>
<td>Public health education</td>
<td></td>
</tr>
<tr>
<td>Professional education</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>22.4%</td>
</tr>
</tbody>
</table>

#### Total Expenses

<table>
<thead>
<tr>
<th>Item</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>24.2%</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>36.0%</td>
</tr>
<tr>
<td>Public health education</td>
<td>14.6%</td>
</tr>
<tr>
<td>Professional education</td>
<td>2.8%</td>
</tr>
<tr>
<td>Management and general</td>
<td>8.3%</td>
</tr>
<tr>
<td>Fundraising</td>
<td>14.1%</td>
</tr>
<tr>
<td>Total</td>
<td>100.0%</td>
</tr>
</tbody>
</table>
## Consolidated Statement of Cash Flows

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2013 (With comparative amounts for the year ended June 30, 2012) (In thousands)

<table>
<thead>
<tr>
<th>Description</th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cash flows from operating activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in net assets</td>
<td>$(13,375)</td>
<td>$(6,265)</td>
</tr>
<tr>
<td>Adjustments to reconcile change in net assets to net cash provided by operating activities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net (increase) decrease in fair value of investments</td>
<td>(9,689)</td>
<td>155</td>
</tr>
<tr>
<td>Permanently restricted contributions collected</td>
<td>—</td>
<td>(257)</td>
</tr>
<tr>
<td>Depreciation and amortization</td>
<td>3,050</td>
<td>2,788</td>
</tr>
<tr>
<td>Increase in allowance for uncollectible accounts</td>
<td>14</td>
<td>40</td>
</tr>
<tr>
<td>Changes in operating assets and liabilities:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>1,161</td>
<td>(1,545)</td>
</tr>
<tr>
<td>Legacies and contributions receivable</td>
<td>(2,627)</td>
<td>14,161</td>
</tr>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>1,192</td>
<td>2,481</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>17,337</td>
<td>496</td>
</tr>
<tr>
<td>Grants payable</td>
<td>8,096</td>
<td>2,387</td>
</tr>
<tr>
<td><strong>Net cash provided by operating activities</strong></td>
<td>5,159</td>
<td>14,421</td>
</tr>
<tr>
<td><strong>Cash flows from investing activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Purchases of fixed assets</td>
<td>(7,049)</td>
<td>(4,209)</td>
</tr>
<tr>
<td>Purchases of investments</td>
<td>(54,862)</td>
<td>(94,729)</td>
</tr>
<tr>
<td>Sales of investments</td>
<td>58,080</td>
<td>92,366</td>
</tr>
<tr>
<td><strong>Net cash used in investing activities</strong></td>
<td>(3,831)</td>
<td>(6,572)</td>
</tr>
<tr>
<td><strong>Cash flows from financing activities:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Permanently restricted contributions collected</td>
<td>—</td>
<td>257</td>
</tr>
<tr>
<td><strong>Net cash provided by financing activities</strong></td>
<td>—</td>
<td>257</td>
</tr>
<tr>
<td><strong>Net increase in cash and cash equivalents</strong></td>
<td>1,328</td>
<td>8,106</td>
</tr>
<tr>
<td>Cash and cash equivalents at beginning of year</td>
<td>25,972</td>
<td>17,866</td>
</tr>
<tr>
<td><strong>Cash and cash equivalents at end of year</strong></td>
<td>$27,300</td>
<td>$25,972</td>
</tr>
</tbody>
</table>

See accompanying notes to consolidated financial statements.
LLS invests in various investment securities. Investment securities are exposed to various risks such as interest rate risks, fluctuations in market security values, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the consolidated balance sheet.

Risk and Uncertainties

1. Organization and Summary of Significant Accounting Policies

Organization

The Leukemia & Lymphoma Society, Inc. (LLS) exists to find cures for blood cancers and ensure access to treatments for blood cancer patients. LLS is the world’s largest voluntary health agency dedicated to finding cures for blood cancer. Our mission is to cure leukemia, lymphoma, Hodgkin’s disease and myeloma and improve the quality of life of patients and improve support for their families. LLS research grants have funded many of today’s most promising advances for the treatment of blood cancer patients, including targeted therapies and immunotherapies. LLS is a leading source of publicly available information for blood cancer, education and support, and drives policies that accelerate the development and approval of new blood cancer therapies. LLS advocates for blood cancer patients and their families, helping patients navigate their cancer treatments and ensuring they have access to quality, affordable and coordinated care.

Tax-Exempt Status

LLS qualifies as a charitable organization as defined by Internal Revenue Code Section 501(c)(3) and, accordingly, is exempt from federal income taxes under Internal Revenue Code Section 501(a). Additionally, since LLS is publicly supported, contributions to LLS qualify for the maximum charitable contribution deduction under the Internal Revenue Code.

The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) is registered as a charitable organization under the Income Tax Act (Canada) and is, therefore, not subject to income taxes if certain disbursement requirements are met.

LLS recognizes the effect of income tax positions only if those tax positions are more likely than not to be sustained. Income generated from activities unrelated to LLS’s exempt purpose is subject to tax under Internal Revenue Code Section 511. LLS did not recognize any unrelated business income tax liability for the years ended June 30, 2013 and 2012.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of LLS, which encompasses the National Office of LLS and its 56 chapters in the United States, LLSC and its five chapters in Canada, and LLS’s not-for-profit affiliates, The Leukemia & Lymphoma Society Research Programs, Inc., and The Leukemia & Lymphoma Society Research Foundation. All significant intercompany and intra-LLS accounts and transactions have been eliminated in consolidation.

Estimates

The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires LLS’s management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The significant estimates made in the preparation of these consolidated financial statements include the fair value of alternative investments, the allowance for uncollectible accounts, the allocation of expenses, and the valuation of donated services and media. Actual results could differ from those estimates.

Risks and Uncertainties

LLS’s principal source of revenue is amounts contributed by the general public. Accordingly, LLS’s operations are impacted by individual contributions, which are impacted by general economic conditions, employment levels, and other factors over which LLS has little or no control. By contrast to the granularity of the general public donations, the co-pay program in 2013 and 2012 was funded by five donors.

Summarized Financial Information

The consolidated financial statements are presented with 2012 summarized or comparative information. With respect to the consolidated statement of activities, such prior year information is not presented by net asset class and, in the consolidated statement of functional expenses, 2012 expenses by object are presented in total rather than by functional category. Accordingly, such information should be read in conjunction with LLS’s 2012 consolidated financial statements from which the summarized information was derived.

Subsequent Events

LLS evaluated subsequent events after the balance sheet date of June 30, 2013 through September 18, 2013, which was the date the consolidated financial statements were issued, and concluded that no additional disclosures are required.

Net Asset Classifications

To ensure observance of limitations and restrictions placed on the use of resources available to LLS, funds that have similar characteristics have been classified into three net asset categories as follows:

- **Unrestricted net assets:** Consist of funds that are fully available, at the discretion of LLS’s Board of Directors, for LLS to utilize in any of its programs or supporting services.
- **Temporarily restricted net assets:** Consist of funds that are restricted by donors for a specific time period and/or purpose.
- **Permanently restricted net assets:** Consist of funds that contain donor-imposed restrictions requiring that the principal be invested in perpetuity. Income earned on these funds are recorded as temporarily restricted net assets and are released from restriction when the donor stipulated purpose has been fulfilled and/or the amount has been appropriated in compliance with the Board-approved spending policy (note 4).

Foreign Currency Translation

LLSC uses the Canadian dollar as its functional currency. Accordingly, the currency impact of the translation of the financial statements of LLSC to U.S. dollars is included as a translation adjustment in the consolidated statement of activities.

Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The three levels of the fair value hierarchy are as follows:

- **Level 1** inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that a reporting entity has the ability to access at the measurement date.
- **Level 2** inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
- **Level 3** unobservable inputs for the asset or liability.

Level 3 inputs for the fair value measurements consist of the following:

<table>
<thead>
<tr>
<th>Description</th>
<th>Number of Level 3 assets as of June 30, 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investment securities</td>
<td>5</td>
</tr>
</tbody>
</table>

Level 3 valuation techniques are applied to the following investments as of June 30, 2013:

<table>
<thead>
<tr>
<th>Description</th>
<th>Number of Level 3 assets as of June 30, 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investment securities</td>
<td>5</td>
</tr>
</tbody>
</table>

Level 3 inputs for the fair value measurements consist of the following investments as of June 30, 2013:

<table>
<thead>
<tr>
<th>Description</th>
<th>Number of Level 3 assets as of June 30, 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investment securities</td>
<td>5</td>
</tr>
</tbody>
</table>
LLS follows the provisions of Accounting Standards Codification (ASC) 820, *Fair Value Measurement*, for its alternative investments that do not have readily determinable fair values, including hedge funds, limited partnerships, and other funds. This guidance allows, as a practical expedient, for the fair value of investments in investment companies for which the investment does not have a readily determinable fair value, using net asset value per share or its equivalent, as reported by the investment managers.

Most investments classified in Levels 2 and 3 consist of shares or units in investment funds as opposed to direct interests in the funds’ underlying holdings, which may be marketable. Because the net asset value reported by each fund is used as a practical expedient to estimate the fair value of LLS’s interest therein, its classification in Level 2 or 3 is based on LLS’s ability to redeem its interest at or near June 30. If the interest can be redeemed in the near term, the investment is classified as Level 2. The classification of investments in the fair value hierarchy is not necessarily an indication of the risks, liquidity, or degree of difficulty in estimating the fair value of each investment’s underlying assets and liabilities.

The carrying value of cash and cash equivalents, accounts payable and accrued expenses, and grants payable approximates fair value because of their short term nature.

**Contributions, Grants and Deferred Revenue**

Contributions are recorded as revenue, at their fair value, when received or promised unconditionally. Contributions received with donor restrictions that limit their use are reported as either temporarily or permanently restricted revenue. When a donor restriction is met through the passage of time or fulfillment of a purpose restriction, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the consolidated statement of activities as net assets released from restrictions. Conditional contributions are recognized as revenue when the conditions have been substantially met. Certain grants are accounted for as exchange transactions whereby revenue is recognized when the related expenses are incurred. Amounts received under these arrangements but not yet expended are reported as deferred revenue.

**Donated Services**

LLS has determined that certain of the donated services it receives meet the criteria for recognition in the consolidated financial statements. The value of contributed services was determined for volunteers who possess specialized skills, and would otherwise need to be purchased. These services are recognized as revenue and expense.

**Donated Media**

During 2013, LLS has conducted a national public service announcement (PSA) media campaign and benefited from donated media time that was aired on television and radio. The value of contributed media was estimated based on the placement, audience, and demographics of the PSA’s. These services are recognized as revenue and expense.

**Cash Equivalents**

Cash equivalents consist of short-term investments with an original maturity of three months or less from date of purchase, except for amounts held for long-term purposes reported as investments.

**Investments**

Investments are stated at fair value based upon quoted market prices, except for the fair values of alternative investments which are based on net asset values provided by the fund managers or general partners, based upon the underlying net assets of the funds consistent with the concepts of ASC 820. These values are reviewed and evaluated by management.

**Fixed Assets and Depreciation**

Fixed assets, which consist principally of equipment, software, and leasehold improvements, are recorded at cost, and are depreciated or amortized using the straight-line method over the estimated useful lives of the assets or the terms of the leases, if shorter, ranging two to 10 years (leasehold improvements seven years; furniture, fixtures, and office equipment seven to 10 years, and computer equipment and software two to five years).

**Professional Fees**

Professional fees included in the consolidated financial statements principally include fundraising counsel fees, data processing services, contracted temporary staffing, contracted software development, and legal and auditing fees.

**Reclassifications**

Certain reclassifications of 2012 amounts have been made to conform to the 2013 presentation.

### 2. Research and Patient Assistance

LLS has various activities that are utilized to carry out its mission as presented below:

a) **Awards and Grants**: Awards and grants for research are approved by LLS’s Board of Directors and are recognized as expense when conditions have been satisfied. The budgets for multi-year grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of LLS’s Board of Directors. LLS has multi-year grant commitments of $93,508,000 at June 30, 2013 which are conditioned upon future events and, accordingly, are not recorded. LLS has unconditional grants payable of $74,825,000 and $68,315,000 at June 30, 2013 and 2012, respectively, which are anticipated to be paid in the next year.

b) **Therapy Acceleration Program (TAP)**: TAP is LLS’s strategic initiative to speed the development of blood cancer treatments and supportive diagnostics by creating business alliances with biotechnology and pharmaceutical companies. TAP provides funding for investigational new drug-enabling studies and clinical-stage projects. TAP contracts are recognized as an expense in the year program milestones are achieved. Multi-year contracts, which are generally two to three years in length, are reviewed against milestones on a quarterly basis and may be terminated at the discretion of LLS’s Board of Directors. LLS has contract commitments of $40,964,000 and $19,078,000 at June 30, 2013 and 2012, respectively, that are conditioned upon future events and, accordingly, are not recorded.

c) **Co-Pay Assistance Program**: The Co-Pay Assistance Program offers financial assistance to patients in meeting their insurance co-pay obligations for prescription medications or private/public health insurance premiums. Amounts awarded under the program are expensed in the year awarded based on the available funding in the program. Approximately $7,237,000 and $5,651,000 were included in the grants payable balances for amounts awarded but unpaid at June 30, 2013 and 2012, respectively.

As discussed above, commitments for the awards and grants and TAP programs are contingent upon the satisfactory completion of milestones and/or other conditions in the grant and contract agreements. If such conditions are satisfied, the amounts are estimated to be paid as follows (in thousands):

<table>
<thead>
<tr>
<th>Year ending June 30:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>$61,285</td>
</tr>
<tr>
<td>2015</td>
<td>42,313</td>
</tr>
<tr>
<td>2016</td>
<td>22,986</td>
</tr>
<tr>
<td>2017 and thereafter</td>
<td>7,888</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$134,472</strong></td>
</tr>
</tbody>
</table>
3. Investments

The following tables present LLS’s fair value hierarchy of investments measured at fair value on an annual basis as of June 30, 2013 and 2012 (in thousands):

Money market funds and cash  
2013  Level 1  Level 2  Level 3  
$ 1,071  $ 1,071  $ -  $ -  

Fixed income:  
Long duration fixed income (mutual fund)  
2013  Level 1  Level 2  Level 3  
63,003  63,003  $ -  $ -  

Short duration fixed income (mutual fund)  
2013  Level 1  Level 2  Level 3  
32,316  32,316  $ -  $ -  

U.S. Treasury Inflation-Protected Security fund (TIPS) and other  
2013  Level 1  Level 2  Level 3  
3,231  940  2,291  -  

Equities:  
Large cap equity  
2013  Level 1  Level 2  Level 3  
6,901  6,901  $ -  $ -  

International equity  
2013  Level 1  Level 2  Level 3  
9,739  9,739  $ -  $ -  

Small/mid cap equity  
2013  Level 1  Level 2  Level 3  
2,022  2,022  $ -  $ -  

Alternative investments:  
Multistrategy hedge funds  
2013  Level 1  Level 2  Level 3  
58,323  -  58,323  -  

Long/short equities  
2013  Level 1  Level 2  Level 3  
3,358  -  -  3,358  

Real assets  
2013  Level 1  Level 2  Level 3  
7,855  -  7,855  -  

Limited partnership equity indices  
2013  Level 1  Level 2  Level 3  
2,736  -  -  2,736  

Total  
2013  Level 1  Level 2  Level 3  
$190,555  $115,992  $71,205  $3,358  

Investment expenses of $1,301,000 and $625,000 have been netted against the net increase in fair value of investments for the years ended June 30, 2013 and 2012, respectively. The unrealized gains and (losses) were $3,810,000 and ($5,514,000) for the years ended June 30, 2013 and 2012, respectively.

LLS’s alternative investments are diversified across four investment strategies, as follows:

1. Multistrategy hedge funds – represent investments in a broad range of investment strategies that seek to exploit opportunities as they occur in the markets due to temporary dislocations or structural inefficiencies and include event-driven strategies, distressed debt, merger and other arbitrage, and value investing.

2. Long/short equities – primarily investments in funds that, in turn, invest in liquid, marketable securities, attempting to realize gains through the identification of mispriced securities.

3. Real asset strategy – passively managed real asset portfolios comprised of REIT Index, commodities, and global natural resource stocks.

4. Limited partnership equity indices – The underlying holdings of the limited partnership equity indices are principally domestic and international marketable securities.

These strategies create indirect exposure to LLS through short sales of securities, trading in future and forward contracts, and other derivative products. Derivatives are investment contracts used to hedge risk. While these financial instruments may contain varying degrees of risk, LLS’s risk with respect to such transactions is limited to its capital balance in each investment.

LLS’s alternative investments contain various redemption restrictions with required written notice ranging from 1 to 95 days. By contrast, all of LLS’s non-alternative investments are highly liquid and can be redeemed daily without restriction. As of June 30, 2013, the following table summarizes the composition of such alternative investments at fair value by the various redemption provisions (in thousands):

<table>
<thead>
<tr>
<th>Redemption period</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daily</td>
<td>2,291</td>
</tr>
<tr>
<td>Monthly</td>
<td>2,736</td>
</tr>
<tr>
<td>Quarterly</td>
<td>66,178</td>
</tr>
<tr>
<td>Annual</td>
<td>3,358</td>
</tr>
<tr>
<td>Total</td>
<td>74,563</td>
</tr>
</tbody>
</table>

As of June 30, 2013 and 2012, LLS has no unfunded commitments on its alternative investments.

The following table presents a reconciliation for all Level 3 assets measured at fair value as of June 30, 2013 and 2012 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Money market funds and cash</td>
<td>$ 1,071</td>
</tr>
<tr>
<td>Fixed income:</td>
<td></td>
</tr>
<tr>
<td>Long duration fixed income (mutual fund)</td>
<td>$ 63,003</td>
</tr>
<tr>
<td>Short duration fixed income (mutual fund)</td>
<td>$ 32,316</td>
</tr>
<tr>
<td>U.S. Treasury Inflation-Protected Security fund (TIPS) and other</td>
<td>$ 3,231</td>
</tr>
<tr>
<td>Equities:</td>
<td></td>
</tr>
<tr>
<td>Large cap equity</td>
<td>$ 6,901</td>
</tr>
<tr>
<td>International equity</td>
<td>$ 9,739</td>
</tr>
<tr>
<td>Small/mid cap equity</td>
<td>$ 2,022</td>
</tr>
<tr>
<td>Alternative investments:</td>
<td></td>
</tr>
<tr>
<td>Multistrategy hedge funds</td>
<td>$ 58,323</td>
</tr>
<tr>
<td>Long/short equities</td>
<td>$ 3,358</td>
</tr>
<tr>
<td>Real assets</td>
<td>$ 7,855</td>
</tr>
<tr>
<td>Limited partnership equity indices</td>
<td>$ 2,736</td>
</tr>
<tr>
<td>Total</td>
<td>$190,555</td>
</tr>
</tbody>
</table>

Balance at July 1  
Purchases  
Investment expense  
Net increase (decrease) in fair value  
Balance at June 30  
$184,084  $141,329  $39,713  $3,042
notes to consolidated financial statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2013 (With comparative amounts as of and for the year ended June 30, 2012)

4. Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets and the income earned on permanently restricted net assets are available for the following purposes at June 30, 2013 and 2012 (in thousands):

LLS follows the provisions of the New York Prudent Management of Institutional Funds Act (NYPMIFA), which imposes guidelines on the management and investment of endowment funds. LLS has interpreted the relevant law as allowing LLS to appropriate for expenditure or accumulate so much of an endowment fund as LLS determines is prudent considering the uses, benefits, purposes, and duration for which the endowment fund is established, subject to the intent of the donor as expressed in the gift instrument.

LLS has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment funds while seeking to protect the original value of the gift. The spending rate policy at June 30, 2013 was 4%, plus any additional amounts advised by donors. Under this policy, the endowment assets are invested in a manner that is intended to produce results consistent with LLS’s overall investment strategy.

The following table presents changes in the donor-restricted endowment funds for the years ending June 30, 2013 and 2012 (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than one year</td>
<td>$ 4,733</td>
<td>$ 3,766</td>
</tr>
<tr>
<td>1 to 5 years</td>
<td>4,130</td>
<td>2,300</td>
</tr>
<tr>
<td>After 5 years</td>
<td>600</td>
<td>712</td>
</tr>
<tr>
<td>Subtotal</td>
<td>9,463</td>
<td>6,778</td>
</tr>
<tr>
<td>Less:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allowance for uncollectible accounts</td>
<td>(792)</td>
<td>(778)</td>
</tr>
<tr>
<td>Discount to present value (1.5% to 5%)</td>
<td>(645)</td>
<td>(587)</td>
</tr>
<tr>
<td>Total</td>
<td>$ 8,026</td>
<td>$ 5,413</td>
</tr>
</tbody>
</table>

Leasehold improvements

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Furniture, fixtures, and other office equipment</td>
<td>2,626</td>
<td>2,881</td>
</tr>
<tr>
<td>Computer equipment and software</td>
<td>18,432</td>
<td>14,303</td>
</tr>
<tr>
<td>Total</td>
<td>$ 22,101</td>
<td>$ 18,228</td>
</tr>
<tr>
<td>Less accumulated depreciation and amortization</td>
<td>(11,248)</td>
<td>(11,374)</td>
</tr>
<tr>
<td>Fixed assets, net</td>
<td>$ 10,853</td>
<td>$ 6,854</td>
</tr>
</tbody>
</table>

Fully depreciated assets with a cost of $3,176,000 were written off in 2013.

5. Legacies and Contributions Receivable

LLS’s legacies and contributions receivable at June 30, 2013 and 2012 consist of unconditional promises to give and legacies for which the underlying wills have been declared valid by the probate court and no other conditions are required to be met. Contributions receivables are originally recorded based on discounted cash flows using a risk adjusted discount rate which is considered a level 3 input in the fair value hierarchy. Amounts are scheduled to be received as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donated services</td>
<td>$ 5,492</td>
<td>$ 5,328</td>
</tr>
<tr>
<td>Donated media</td>
<td>2,258</td>
<td>–</td>
</tr>
<tr>
<td>Total</td>
<td>$ 7,750</td>
<td>$ 5,328</td>
</tr>
</tbody>
</table>

6. Deferred Revenue, Donated Services and Media

During 2013, LLS received a $20 million grant that is planned to be utilized on research which will jointly be identified by the grantor and LLS. At June 30, 2013 these funds were held equally between cash and investments. Revenue under this grant is expected to be recognized over the next four years, as expenses are incurred. At June 30, 2013, the unexpended balance of the grant of $19.5 million is included in deferred revenue. The remaining balance of deferred revenue includes amounts received for special events that will be held subsequent to the fiscal year-end.

The value of donated services for family support group facilitators and research grant reviewers, as well as donated media are included in both revenue and expense as shown below (in thousands):

7. Fixed Assets, Net

Fixed assets at June 30, 2013 and 2012 consist of the following (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leasehold improvements</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Furniture, fixtures, and other office equipment</td>
<td>2,626</td>
<td>2,300</td>
</tr>
<tr>
<td>Computer equipment and software</td>
<td>18,432</td>
<td>14,303</td>
</tr>
<tr>
<td>Total</td>
<td>$ 22,101</td>
<td>$ 18,228</td>
</tr>
</tbody>
</table>
8. Pension Plan

LLS has a defined contribution 403(b) pension plan covering all employees meeting age and service requirements. Contributions are based on a percentage of each eligible employee’s salary and years of service. Expenses under this plan aggregated $4,173,000 and $3,967,000 for the years ended June 30, 2013 and 2012, respectively.

LLS has a 457(b) deferred compensation plan (the 457 Plan), for its executive staff. The 457 Plan is a nonqualified deferred compensation plan subject to the provisions of the Internal Revenue Code Section 457. Expenses under the 457 Plan approximated $195,000 and $157,000 for the years ended June 30, 2013 and 2012, respectively. The assets and liabilities of the 457 Plan are included in investments and accounts payable in the accompanying consolidated balance sheet and amounted to approximately $1,357,000 and $1,196,000 at June 30, 2013 and 2012, respectively.

9. Lease Commitments

The leases for premises, which LLS’s National Office and chapters occupy, expire on various dates through September 30, 2023 and provide for certain payments subject to escalation and periodic rate increases relating to real estate taxes, operating expenses, and utilities. The National Office lease expires in March 2016.

The approximate minimum aggregate future annual rental commitments are summarized as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Fund raising</td>
<td>$10,577</td>
<td>$11,509</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient and community service</td>
<td>1,895</td>
<td>1,049</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Public health education</td>
<td>8,966</td>
<td>9,522</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>$21,438</td>
<td>$22,080</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

10. Joint Costs Allocation

For the years ended June 30, 2013 and 2012, LLS incurred joint costs for informational materials and activities that included fund raising appeals as follows (in thousands):

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2012</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fund raising</td>
<td>$10,577</td>
<td>$11,509</td>
</tr>
<tr>
<td>Patient and community service</td>
<td>1,895</td>
<td>1,049</td>
</tr>
<tr>
<td>Public health education</td>
<td>8,966</td>
<td>9,522</td>
</tr>
<tr>
<td>Total</td>
<td>$21,438</td>
<td>$22,080</td>
</tr>
<tr>
<td>State</td>
<td>City</td>
<td>Address</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Alabama</td>
<td>Birmingham</td>
<td>100 Chace Park South Suite 220</td>
</tr>
<tr>
<td>Alaska</td>
<td>See Washington</td>
<td></td>
</tr>
<tr>
<td>Arizona</td>
<td>Phoenix</td>
<td>3877 North 7th Street Suite 300</td>
</tr>
<tr>
<td>Arkansas</td>
<td>See Missouri</td>
<td></td>
</tr>
<tr>
<td>California</td>
<td>San Diego</td>
<td>340 West Fallbrook Avenue</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delaware</td>
<td>Wilmington</td>
<td>100 West 10th Street Suite 209</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Florida</td>
<td>Hollywood</td>
<td>200 South Park Road Suite 140</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hollywood, FL 33012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3319 Maguire Boulevard Suite 101</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Orlando, FL 32803</td>
</tr>
<tr>
<td>Georgia</td>
<td>See San Diego</td>
<td>3715 Northside Parkway Building 400 Suite 300</td>
</tr>
<tr>
<td>Hawaii</td>
<td>See San Diego</td>
<td></td>
</tr>
<tr>
<td>Idaho</td>
<td>Boise</td>
<td>2404 West Bank Drive Suite 103</td>
</tr>
<tr>
<td>Illinois</td>
<td>Chicago</td>
<td>651 West Washington Boulevard Suite 400</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Chicago, IL 60611</td>
</tr>
<tr>
<td>Indiana</td>
<td>See Indianapolis</td>
<td>9075 N Meridian St Suite 150</td>
</tr>
<tr>
<td>Iowa</td>
<td>Des Moines</td>
<td>2700 Westtown Pkwy Suite 260</td>
</tr>
<tr>
<td>Kansas</td>
<td>Topeka</td>
<td>6811 Shawnee Mission Parkway</td>
</tr>
<tr>
<td>Louisiana</td>
<td>New Orleans</td>
<td>300 North Main Suite 300</td>
</tr>
<tr>
<td>Kentucky</td>
<td>Louisville</td>
<td>301 East Main Street Suite 100</td>
</tr>
<tr>
<td>Louisiana</td>
<td>Metairie</td>
<td>3636 South 1st Service Road Suite 304</td>
</tr>
<tr>
<td>Maine</td>
<td>See Massachusetts</td>
<td></td>
</tr>
<tr>
<td>Maryland</td>
<td>Owings Mills</td>
<td>100 Painters Mill Road Suite 800</td>
</tr>
<tr>
<td>Massachusetts</td>
<td>Erie Drive</td>
<td>9 Erie Drive</td>
</tr>
<tr>
<td>Michigan</td>
<td>See Minneapolis</td>
<td>1711 Broadway Street NE</td>
</tr>
<tr>
<td>Minnesota</td>
<td>Minneapolis</td>
<td>401 Harrison Oaks Boulevard Suite 200</td>
</tr>
<tr>
<td>Missouri</td>
<td>St. Louis</td>
<td>77 West Port Plaza Suite 480</td>
</tr>
<tr>
<td>Montana</td>
<td>See Oregon</td>
<td>7200 Commonwealth Boulevard Suite 80</td>
</tr>
<tr>
<td>Nebraska</td>
<td>Bismarck</td>
<td>12100 W Center Road Blvd.</td>
</tr>
<tr>
<td>Nevada</td>
<td>Las Vegas</td>
<td>6280 South Valley View Boulevard Suite 342</td>
</tr>
<tr>
<td>New Hampshire</td>
<td>Concord</td>
<td>9320 SW Barbur Boulevard Suite 300</td>
</tr>
<tr>
<td>New Jersey</td>
<td>Trenton</td>
<td>14 Commerce Drive Suite 301</td>
</tr>
<tr>
<td>New Mexico</td>
<td>Albuquerque</td>
<td>4600-A Montgomery Boulevard NE Suite 201</td>
</tr>
<tr>
<td>New York</td>
<td>5 Computer Drive Suite 100</td>
<td>5043 Maple Road Suite 105</td>
</tr>
<tr>
<td>Rhode Island</td>
<td>311 Mamaroneck Avenue Suite 130</td>
<td>61 Broadway-Suite 400</td>
</tr>
<tr>
<td>South Carolina</td>
<td>107 Westminster Boulevard Suite 600</td>
<td>100 North Main Suite 501</td>
</tr>
<tr>
<td>South Dakota</td>
<td>See Minnesota</td>
<td>100 Painters Mill Road Suite 800</td>
</tr>
<tr>
<td>Tennessee</td>
<td>See Minneapolis</td>
<td></td>
</tr>
<tr>
<td>Texas</td>
<td>Dallas</td>
<td>8111 LBJ Freeway Suite 425</td>
</tr>
<tr>
<td>Texas</td>
<td>Austin</td>
<td>1218 Arion Parkway Suite 102</td>
</tr>
<tr>
<td>North Dakota</td>
<td>See Minnesota</td>
<td></td>
</tr>
<tr>
<td>Utah</td>
<td>5296 Commerce Drive Suite 101</td>
<td></td>
</tr>
<tr>
<td>Vermont</td>
<td>See Albany</td>
<td></td>
</tr>
<tr>
<td>Virginia</td>
<td>Richmond</td>
<td>555 North Lane Suite 501</td>
</tr>
<tr>
<td>Washington</td>
<td>See Pittsburgh</td>
<td>200 South Executive Drive Suite 203</td>
</tr>
<tr>
<td>Wisconsin</td>
<td>See Brookfield</td>
<td>300 North Main Suite 300</td>
</tr>
<tr>
<td>West Virginia</td>
<td>See Pittsburgh</td>
<td></td>
</tr>
<tr>
<td>Wyoming</td>
<td>See Colorado</td>
<td></td>
</tr>
</tbody>
</table>

** PUERTO RICO **

Comercial 18                          800 Roberto H. Todd Avenue Suite 206
San Juan, PR 00907                  775.725.2200

** CANADA **

Canada Corporate                      804-2 Lansdowne Square
Toronto, ON M2J 4P8              416.661.9541 x104
Atlantic Canada Region               1690 Hollis Street, HS2
Halifax, NS B3J 1V7           902.422.5999
BC/Yukon Region                      1682 West 7th Avenue Suite 310
Vancouver, BC V6J 4G6         604.733.2873
Ontario Region                      1502-480 University Avenue
Toronto, ON MSF 1V2            416.585.2873
Prairies Region                     2020 10th Street NW
Calgary, AB T2M 3M2           403.263.5300
Région de Québec                    705-1255 University Street
Montréal, QC H3B 3W1        514.875.1000
our mission: cure leukemia, lymphoma, hodgkin’s disease and myeloma, and improve the quality of life of patients and their families

we can really do this

go to lls.org/donate today